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Abstract 
Nitric oxide (NO) is synthesized via distinct NO synthase (NOS) enzymes and constitutes an 
essential cardiovascular signaling molecule.  Whereas important vasomotor contributions of 
endothelial NOS (eNOS) have been well-described, the specific vasomotor contributions of 
nNOS-derived NO in healthy subjects during exercise are unknown.  The purpose of this 
dissertation is to test the global hypothesis that nNOS-derived NO is a critical regulator of 
exercising skeletal muscle vascular control.  Specifically, we utilized the selective nNOS 
inhibitor S-methyl-L-thiocitrulline (SMTC) to investigate the effects of nNOS-derived NO on 
skeletal muscle vascular function within established rodent models of exercise performance.  The 
first investigation (Chapter 2) identifies that nNOS inhibition with SMTC increases mean arterial 
pressure (MAP) and reduces rat hindlimb skeletal muscle blood flow at rest whereas there are no 
effects during low-speed (20 m/min) treadmill running.  In Chapter 3 it is reported that nNOS 
inhibition with SMTC reduces blood flow during high-speed treadmill running (>50 m/min) with 
the greatest relative effects found in highly glycolytic fast-twitch muscles and muscle parts.  
Chapter 4 demonstrates that nNOS-derived NO modulates contracting skeletal muscle blood 
flow (increases), O2 consumption ( 2OV
 , increases), and force production (decreases) in the rat 
spinotrapezius muscle and thus impacts the microvascular O2 delivery- 2OV
  ratio (which sets the 
microvascular partial pressure of O2, PO2mv, and represents the pressure head that drives 
capillary-myocyte O2 diffusion).  In Chapter 5 we report that systemic administration of the 
selective nNOS inhibitor SMTC does not impact lumbar sympathetic nerve discharge.  This 
reveals that the SMTC-induced peripheral vascular effects described herein reflect peripheral 
nNOS-derived NO signaling as opposed to centrally-derived regulation.  In conclusion, nNOS-
derived NO exerts exercise-intensity and muscle fiber-type selective peripheral vascular effects 
during whole-body locomotor exercise. In addition, nNOS-derived NO modulates skeletal 
muscle contractile and metabolic function and, therefore, impacts the skeletal muscle PO2mv.  
These data identify novel integrated roles for nNOS-derived NO within healthy skeletal muscle 
and have important implications for populations associated with reduced NO bioavailability 
and/or impaired nNOS structure and/or function specifically (e.g., muscular dystrophy, chronic 
heart failure, advanced age, etc.). 
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Abstract 
Nitric oxide (NO) is synthesized via distinct NO synthase (NOS) enzymes and constitutes an 
essential cardiovascular signaling molecule.  Whereas important vasomotor contributions of 
endothelial NOS (eNOS) have been well-described, the specific vasomotor contributions of 
nNOS-derived NO in healthy subjects during exercise are unknown.  The purpose of this 
dissertation is to test the global hypothesis that nNOS-derived NO is a critical regulator of 
exercising skeletal muscle vascular control.  Specifically, we utilized the selective nNOS 
inhibitor S-methyl-L-thiocitrulline (SMTC) to investigate the effects of nNOS-derived NO on 
skeletal muscle vascular function within established rodent models of exercise performance.  The 
first investigation (Chapter 2) identifies that nNOS inhibition with SMTC increases mean arterial 
pressure (MAP) and reduces rat hindlimb skeletal muscle blood flow at rest whereas there are no 
effects during low-speed (20 m/min) treadmill running.  In Chapter 3 it is reported that nNOS 
inhibition with SMTC reduces blood flow during high-speed treadmill running (>50 m/min) with 
the greatest relative effects found in highly glycolytic fast-twitch muscles and muscle parts.  
Chapter 4 demonstrates that nNOS-derived NO modulates contracting skeletal muscle blood 
flow (increases), O2 consumption ( 2OV
 , increases), and force production (decreases) in the rat 
spinotrapezius muscle and thus impacts the microvascular O2 delivery- 2OV
  ratio (which sets the 
microvascular partial pressure of O2, PO2mv, and represents the pressure head that drives 
capillary-myocyte O2 diffusion).  In Chapter 5 we report that systemic administration of the 
selective nNOS inhibitor SMTC does not impact lumbar sympathetic nerve discharge.  This 
reveals that the SMTC-induced peripheral vascular effects described herein reflect peripheral 
nNOS-derived NO signaling as opposed to centrally-derived regulation.  In conclusion, nNOS-
derived NO exerts exercise-intensity and muscle fiber-type selective peripheral vascular effects 
during whole-body locomotor exercise. In addition, nNOS-derived NO modulates skeletal 
muscle contractile and metabolic function and, therefore, impacts the skeletal muscle PO2mv.  
These data identify novel integrated roles for nNOS-derived NO within healthy skeletal muscle 
and have important implications for populations associated with reduced NO bioavailability 
and/or impaired nNOS structure and/or function specifically (e.g., muscular dystrophy, chronic 
heart failure, advanced age, etc.).
vi 
 
 
Table of Contents 
List of Figures .............................................................................................................................. viii 
List of Tables ................................................................................................................................. ix 
Acknowledgements ......................................................................................................................... x 
Preface............................................................................................................................................ xi 
Chapter 1 - Introduction .................................................................................................................. 1 
References ................................................................................................................................... 7 
Chapter 2 - Effects of neuronal nitric oxide synthase inhibition on resting and exercising 
hindlimb muscle blood flow in the rat ................................................................................... 11 
Summary ................................................................................................................................... 12 
Introduction ............................................................................................................................... 13 
Methods .................................................................................................................................... 15 
Results ....................................................................................................................................... 19 
Discussion ................................................................................................................................. 21 
References ................................................................................................................................. 34 
Chapter 3 - Muscle fiber-type dependence of neuronal nitric oxide synthase-mediated vascular 
control in the rat during high-speed treadmill running .......................................................... 39 
Summary ................................................................................................................................... 40 
Introduction ............................................................................................................................... 41 
Methods .................................................................................................................................... 43 
Results ....................................................................................................................................... 48 
Discussion ................................................................................................................................. 50 
References ................................................................................................................................. 63 
Chapter 4 - Role of neuronal nitric oxide synthase in modulating skeletal muscle microvascular 
and contractile function ......................................................................................................... 67 
Summary ................................................................................................................................... 68 
Introduction ............................................................................................................................... 69 
Methods .................................................................................................................................... 71 
Results ....................................................................................................................................... 77 
Discussion ................................................................................................................................. 79 
vii 
 
References ................................................................................................................................. 92 
Chapter 5 - Neuronal nitric oxide synthase inhibition and regional sympathetic nerve discharge: 
implications for peripheral vascular control .......................................................................... 98 
Summary ................................................................................................................................... 99 
Introduction ............................................................................................................................. 100 
Methods .................................................................................................................................. 101 
Results ..................................................................................................................................... 104 
Discussion ............................................................................................................................... 105 
References ............................................................................................................................... 111 
Chapter 6 - Conclusions .............................................................................................................. 114 
Appendix A - Curriculum Vitae ................................................................................................. 116 
 
viii 
 
 
List of Figures 
Figure 1.1. Unanswered questions regarding physiological roles of nNOS-derived NO ............... 6 
Figure 2.1. Effects of nNOS inhibition on resting skeletal muscle blood flow and VC ............... 28 
Figure 2.2. Relationships between changes in resting blood flow and VC following SMTC and 
muscle fiber-type composition .............................................................................................. 29 
Figure 2.3. Relationships between resting blood flow and VC and the changes in resting blood 
flow and VC .......................................................................................................................... 30 
Figure 2.4. Effects of nNOS inhibition on exercising skeletal muscle blood flow and VC ......... 31 
Figure 2.5. Effects of nNOS inhibition on resting and exercising MAP and HR ......................... 32 
Figure 2.6. Effects of SMTC and L-NAME on the hypotensive response to ACh ...................... 33 
Figure 3.1. Estimation of critical speed for a representative rat ................................................... 58 
Figure 3.2. Effects of nNOS inhibition on hindlimb skeletal muscle blood flow and VC ........... 59 
Figure 3.3. Relative changes in blood flow and VC following nNOS inhibition ......................... 60 
Figure 3.4. Relative changes in blood flow and VC following nNOS inhibition ......................... 61 
Figure 3.5. MAP data demonstrating the efficacy and selectivity of nNOS inhibition ................ 62 
Figure 4.1. Effects SMTC and L-NAME on the hypotensive response to ACh ........................... 86 
Figure 4.2. Effects of SMTC infusion on PO2mv ......................................................................... 87 
Figure 4.3. Effects of nNOS inhibition on contracting muscle PO2mv ........................................ 88 
Figure 4.4. Effects of nNOS inhibition on spinotrapezius muscle blood flow and VC ................ 89 
Figure 4.5. Effects of nNOS inhibition on spinotrapezius muscle 2OV
  ....................................... 90 
Figure 4.6. Effects of nNOS inhibition on spinotrapezius muscle force production .................... 91 
Figure 5.1. Original tracings of lumbar and renal SND from a representative rat ..................... 108 
Figure 5.2. Effects of saline and SMTC infusions on lumbar and renal SND ............................ 109 
Figure 5.3. Effects of saline and SMTC infusions on MAP and HR .......................................... 110 
Figure 6.1. Summary of results ................................................................................................... 115 
 
ix 
 
 
List of Tables 
Table 2.1. Effects of nNOS inhibition on resting skeletal muscle blood flow and VC ................ 26 
Table 2.2. Effects of nNOS inhibition on kidney and splanchnic organ blood flow and VC....... 27 
Table 3.1. Effects of nNOS inhibition on MAP and HR .............................................................. 54 
Table 3.2. Effects of nNOS inhibition on blood flow and VC ..................................................... 55 
Table 3.3. Effects of nNOS inhibition on blood flow and VC ..................................................... 57 
Table 4.1. Effects of nNOS inhibition on HR and MAP .............................................................. 84 
Table 4.2. Effects of nNOS inhibition on contracting skeletal muscle PO2mv parameters .......... 85 
 
x 
 
 
Acknowledgements 
I am deeply indebted to the many wonderful individuals who have helped make my 
graduate school experience simultaneously rewarding, challenging, productive, and fun. 
First, I am extremely grateful for the outstanding academic mentorship of my major 
professor, Dr. Timothy Musch, who was willing to take a chance and allow an unknown student 
to wander into his research laboratory in the fall of 2006.  I would like also like to thank Dr. 
David Poole for his vital role in my professional development and assure him that I will never 
take anyone at their word but demand to see the scientific evidence for myself.  Together, Dr. 
Musch and Dr. Poole have taught me the importance and value of scientific research while 
providing constant reminders that academic and professional success is only a worthwhile 
pursuit if I enjoy what I am doing.  
In addition to Dr. Musch and Dr. Poole, I am grateful for the professional and scientific 
influence, guidance, and critique from my committee members: Dr. Michael Kenney, Dr. 
Thomas Barstow, Dr. Craig Harms, and Dr. Mark Haub. 
I am grateful to the many former and current Musch/Poole students with whom I have 
shared lab (and LAB) time with including Sue Hageman, Dr. Leonardo Ferreira, Kyle Herspring, 
Lauren McDaniel, Dr. Robert Davis, Peter Schwagerl, Scott Ferguson, Clark Holdsworth, and 
Gabi Sims.  Special gratitude is reserved for Dr. Daniel Hirai with whom the majority of my 
graduate studies and LAB time have overlapped. 
I would like to thank my parents for always supporting me in my decision to pursue 
graduate training.  Finally, I owe a special thanks to my wife Melissa and daughter Kieryn for 
always supporting me, encouraging me, and understanding that rats still need to run on 
Saturdays. 
 
xi 
 
 
Preface 
Chapters 2-5 of this dissertation represent original research articles that have been published or 
accepted for publication following the peer-review process (citations may be found below).  
They are reproduced here with permission from the publishers. 
 
Copp SW, Hirai DM, Schwagerl PJ, Musch TI, and Poole DC. Effects of neuronal nitric 
oxide synthase inhibition on resting and exercising hindlimb muscle blood flow in the rat. 
J Physiol 588, 1321-1331, 2010. 
 
Copp SW, Holdsworth CT, Ferguson SK, Hiari DM, Poole DC and Musch TI. Muscle fibre-
type dependence of neuronal nitric oxide synthase-mediated vascular control in the rat 
during high speed treadmill running. J Physiol In press, 
doi:10.1113/jphysiol.2013.251082. 
 
Copp SW, Hirai DM, Ferguson SK, Musch TI, and Poole DC. Role of neuronal nitric oxide 
synthase in modulating microvascular and contractile function in rat skeletal muscle. 
Microcirculation 18, 501-511, 2011. 
 
Copp SW, Hirai DM, Sims GE, Musch TI, Poole DC, and Kenney MJ. Neuronal nitric oxide 
synthase inhibition and regional sympathetic nerve discharge: implications for peripheral 
vascular control. Resp Phys Neurobiol 186: 285-289.
1 
 
 
Chapter 1 - Introduction 
Elevations in skeletal muscle metabolic demand during exercise are supported by robust 
increases in skeletal muscle blood flow and, therefore, O2 delivery.  Specifically, skeletal muscle 
blood flow increases 5-6 liters for every 1 liter increase in muscle O2 consumption ( 2OV
 ) across 
the spectrum of muscle fiber-type compositions (2).  This tight coupling serves to constrain the 
fall in skeletal muscle microvascular O2 pressure (PO2mv, which reflects the skeletal muscle O2 
delivery/ 2OV
  ratio) during contractions preserving the pressure head driving capillary-myocyte 
O2 diffusion.  The increase in muscle blood flow during exercise is accomplished via complex 
interactions among neurohumoral activation (to increase cardiac output and facilitate peripheral 
blood flow redistribution to working skeletal muscle), local mechanical vascular influences (e.g., 
muscle pump and arteriolar compression-mediated vasodilation), and metabolic and humoral 
vasodilators (17, 31).  However, resolution of the specific spatial and temporal actions of the 
various vasomotor regulators has proved elusive owing to the highly redundant and synergistic 
nature of the exercise hyperemic control (17). 
 Among the numerous putative vasodilator candidates, perhaps none has been so 
extensively investigated as the biological cardiovascular signaling molecule nitric oxide (NO).  
This is true despite the relatively recent history of NO-related research.  Gruetter et al. (9) 
originally identified the smooth muscle relaxant properties of NO via its application within an 
organ bath containing pre-contracted strips of bovine coronary arteries.  In 1980, a landmark 
paper by Furchgott and Zawadzki (5) identified that an intact endothelium was required to elicit 
vasodilation in response to acetylcholine and the term “endothelial-derived relaxing factor” 
(EDRF) was coined.  It was not until 1987 that two groups working independently demonstrated 
that EDRF was in fact NO (16, 27).  Only one year later came the observation that the amino 
acid L-arginine acted as an obligatory precursor for NO synthesis (26).  Shortly thereafter it was 
identified that a cytosolic calcium-regulated enzyme utilized L-arginine to produce a substance 
that possessed similar vasoactive properties to EDRF (this molecule was not identified definitely 
as NO and consistent use of “NO” rather than “EDRF” was not yet commonplace) and acted 
through soluble guanylate cyclase (21).  Although it was not stated as such at the time, this was 
the first identification of the NO synthase (NOS) enzyme.  Subsequently, the first isolation of 
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NOS was reported in brain tissue (1) although this so called type I NOS or neuronal NOS 
(nNOS) enzyme was later identified to exist also within skeletal muscles (19), the vascular 
endothelium, and neurons (8).  The initial NOS discovery was followed quickly by isolation of 
inducible NOS (type II NOS or iNOS) from macrophages (10) and endothelial NOS (type III 
NOS or eNOS) from endothelial cells of the bovine aorta (28).  Since those seminal studies, NO-
related research has spanned the fields of cardiovascular, immunological/inflammatory, 
neurological, and skeletal muscle/metabolic physiology and medicine (23). 
A significant advancement in NO-related research came with the demonstration that N
G
-
monomethyl-L-arginine (L-NMMA) acted as an inhibitor of NO synthesis.  This constituted a 
valuable experimental tool and opened the door to investigations in which acute pharmacological 
NOS inhibition could be administered to individual preparations/subjects and physiological 
responses could be measured before and after NOS inhibition.  The first report utilizing such a 
strategy came from Rees et al. (29) who observed that L-NMMA administration rapidly and 
robustly increased blood pressure in anesthetized rabbits.  The identification that pressure 
regulation depended on a tonic vasodilator signal, rather than tonic vasoconstriction, changed our 
understanding of cardiovascular and arterial blood pressure control (23).  Importantly, that early 
work on NO and blood pressure regulation was completed prior to the discovery of the various 
NOS isoforms.  Thus, the entirety of the NO-mediated blood pressure control signal was ascribed 
to the only confirmed source of NO production; the endothelium.  The subsequent discoveries of 
the 3 distinct NOS isoforms (which included, of course, eNOS) and the fact that L-NMMA and 
L-NAME lacked specificity for a given isoform did little to quell the commonly held belief that 
eNOS-derived NO was the principal, if not exclusive, peripheral NO-mediated basal blood 
pressure control signal.   
The experimental use of non-selective NOS inhibition via L-NMMA or another L-
arginine analogue N
G
-arginine-methyl-ester (L-NAME) has remained prominent.  For example, 
studies utilizing non-selective NOS inhibition have provided evidence that NO constitutes a key 
vasoactive molecule which contributes importantly to contracting skeletal muscle hyperemia in 
both animals (e.g., 13, 18) and humans (e.g., 12, 32) and controls the temporal matching of the 
contracting muscle PO2mv and changes thereof (3).  While the majority of such investigations 
have failed to identify the specific cardiovascular effects of the distinct NOS isoforms, given the 
central role of the endothelium in shear-stress related signal transduction and vasodilation during 
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exercise, NO-mediated peripheral vascular regulation in exercising muscle has been essentially 
synonymous with endothelial and eNOS-mediated function (39). 
There is limited information regarding the potential vasodilatory roles for nNOS-derived 
NO during exercise in healthy subjects (22).  Evidence supporting vasomotor influences of 
nNOS-derived NO emanates primarily from genetically-altered mouse models in which nNOS 
expression is reduced or absent and the ability to attenuate sympathetic vasoconstrictor signals 
within contracting skeletal muscle is impaired (36, 37).  The ability to modulate sympathetic 
vasoconstriction during forearm contractions is similarly impaired in children with Duchenne 
muscular dystrophy, a disease condition hallmarked by reduced intramuscular nNOS expression 
and muscle weakness (30).  However, the blood flow response to muscle contractions per se was 
preserved in those investigations suggesting no obligatory exercise hyperemic role for nNOS-
derived NO specifically.  It also must be considered that chronic nNOS absence in disease and 
disease models is associated with impaired skeletal muscle growth and function which may 
impact vasomotor signaling pathways (30) and that alternate NOS isoforms may compensate 
when one isoform is altered chronically (14).  Notwithstanding these considerations, given the 
localization of calcium-regulated nNOS near the sarcolemma of skeletal myocytes and the 
unrestricted diffusibility of NO across biological membranes, nNOS-derived NO seems a logical 
paracrine vasodilator candidate responsible for linking skeletal muscle O2 supply to O2 demand; 
an essential feature of exercise hyperemia (17).  Exercise intensity and/or muscle-fiber type 
selective characteristics of nNOS-derived vasomotor regulation are also plausible given that 
nNOS activity is higher in glycolytic fast-twitch versus oxidative slow-twitch rat muscle (19) 
and that the attenuation of sympathetic vasoconstriction is present in glycolytic but not oxidative 
rat muscle during high contraction intensities only (35).  In addition, myoglobin concentration is 
higher in oxidative compared to glycolytic skeletal muscles (11) and it has been demonstrated 
that myoglobin possesses potent NO scavenging properties (4).  Collectively, those observations 
suggest that an nNOS-derived NO vasomotor signal may exist within glycolytic muscles during 
high-intensity exercise, however, direct empirical observations regarding requisite characteristics 
of nNOS-mediated vascular control in healthy subjects are lacking.  Specifically, it remains 
unknown whether nNOS-derived NO vasomotor regulation: 1) contributes importantly to 
skeletal muscle hyperemia in healthy subjects during whole-body locomotor exercise, 2) varies 
as a function of exercise intensity and/or muscle fiber-type composition during voluntary 
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exercise, or 3) occurs concurrent with nNOS-derived NO contractile and metabolic regulation 
(Figure 1.1).   
In 1994, development of the pharmacological selective nNOS inhibitor S-methyl-L-
thiocitrulline (SMTC; 6, 24) afforded the opportunity to investigate the physiological roles of 
nNOS-derived specifically.  Subsequently, marked pressor effects were observed when SMTC 
was administered to intact animals in vivo (7, 25).  Tragically, given the established dogma that 
eNOS-derived NO controlled basal blood pressure, those pressor effects were often interpreted to 
represent SMTC-induced effects on eNOS rather than important physiological contributions 
from nNOS (7, 25, 38).  Thus, the use of SMTC as a means to investigate nNOS-mediated 
function in vivo did not gain significant traction initially.  In 1998, Ichihara and colleagues (15) 
examined the role of nNOS inhibition via SMTC on renal arteriolar function.  Cognizant of the 
concerns regarding the selectivity of SMTC for nNOS over eNOS, the investigators examined 
the vasodilatory response of isolated renal afferent and efferent arterioles to acetylcholine (ACh, 
an eNOS agonist).  The fact that SMTC did not blunt the vasodilatory response to ACh, whereas 
it was completely inhibited following non-selective NOS administration, supported the 
selectivity of SMTC for nNOS.  Moreover, the precedent for the assessment of the selectivity of 
SMTC for nNOS via ACh administration was established (15).  Komers et al. (20) then followed 
with a study utilizing systemically-administered SMTC in rats and demonstrated that low SMTC 
doses do not impact the hypotensive response to systemic ACh infusions whereas they are 
blunted at high SMTC doses (consistent with the loss of selectivity for nNOS at high SMTC 
doses only).  Wakefield et al. (38) subsequently completed an SMTC dose-response assessment 
to various vasoactive agents including ACh, sodium nitroprusside (SNP, an NO donor), 
salbutamol (a beta-2 receptor agonist the effects of which are L-NAME sensitive), and 
bradykinin.  That investigation has provided the strongest support to date for the selectivity of 
nNOS inhibition with systemic low-dose SMTC administration in vivo.  More recently, the 
selectivity of SMTC for nNOS has been confirmed in humans (33, 34) concurrent with the 
demonstration that nNOS-derived NO modulates basal brachial (33) and coronary (34) artery 
blood flow.   
There are currently no investigations that have utilized selective nNOS inhibition with 
SMTC to examine the role of nNOS-derived NO in the regulation of contracting skeletal muscle 
vascular control.  Thus, the overarching purpose of this dissertation is to employ selective nNOS 
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inhibition with SMTC to test the global hypothesis that nNOS-derived NO is a critical regulator 
of skeletal muscle vascular control during exercise in healthy subjects.  Specifically, acute 
systemic SMTC administration was utilized to investigate the effects of nNOS-derived NO on rat 
hindlimb skeletal muscle blood flow and vascular conductance (VC) at rest and during low-
speed treadmill running (Chapter 2).  Given the potential for exercise intensity and muscle-fiber 
type dependency of nNOS-mediated vascular control we examined the effects of SMTC 
administration on skeletal muscle blood flow during high-speed treadmill running above critical 
speed which evokes marked fast-twitch fiber recruitment (Chapter 3).  In anesthetized rats, 
SMTC was employed to examine the influence of nNOS-derived NO on resting skeletal muscle 
PO2mv, the dynamic PO2mv response following the onset of contractions, and skeletal muscle 
metabolic (i.e., 2OV
 ) and contractile function (Chapter 4).  Finally, we investigated the effects of 
systemically-administered SMTC on lumbar sympathetic nerve discharge to dissect the 
contributions of central versus peripheral nNOS inhibition in the previous experiments (Chapter 
5).  Importantly, evidence supporting the efficacy and selectivity of nNOS inhibition is presented 
and discussed within each investigation. 
Chapters 2-5 of this dissertation are self-contained and presented in standard journal 
article format with introduction, methods, results, discussion and reference sections.  The last 
chapter of this dissertation (Chapter 6) provides an overall summary and conclusion which 
synthesizes and integrates the primary findings from the individual studies. 
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Figure 1.1. Unanswered questions regarding physiological roles of nNOS-derived NO 
 
 
 
Schematic representation of the unanswered questions regarding the physiological roles of 
nNOS-derived NO within skeletal muscle and associated vascular beds in healthy subjects.  
2OV
 , O2 consumption; MAP, mean arterial pressure. 
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Chapter 2 - Effects of neuronal nitric oxide synthase inhibition on 
resting and exercising hindlimb muscle blood flow in the rat 
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 Summary 
Nitric oxide (NO) derived from endothelial NO synthase (eNOS) is an integral mediator 
of vascular control during muscle contractions.  However, it is not known whether neuronal NOS 
(nNOS) derived NO regulates tissue hyperemia in healthy subjects, particularly during exercise.  
We tested the hypothesis that selective nNOS inhibition would reduce blood flow and vascular 
conductance (VC) in rat hindlimb locomotor muscle(s), kidneys, and splanchnic organs at rest 
and during dynamic treadmill exercise (20 m/min, 10% grade).  19 male Sprague-Dawley rats 
(555±23 g) were assigned to either rest (n=9) or exercise (n=10) groups.  Blood flow and VC 
were determined via radiolabelled microspheres before and after the intra-arterial administration 
of the selective nNOS inhibitor S-methyl-L-thiocitrulline (SMTC, 2.1±0.1 µmol/kg).  Total 
hindlimb muscle blood flow (control: 20±2, SMTC: 12±2 ml/min/100g, p<0.05) and VC 
(control: 0.16±0.02, SMTC: 0.09±0.01 ml/min/100g/mmHg, p<0.05) were reduced substantially 
at rest.  Moreover, the magnitude of the absolute reduction in blood flow and VC correlated 
(p<0.05) with the proportion of oxidative muscle fibers found in the individual muscles or 
muscle parts of the hindlimb.  During exercise, total hindlimb blood flow (control: 108±7, 
SMTC: 105±8 ml/min/100g) and VC (control: 0.77±0.06; SMTC: 0.70±0.05 
ml/min/100g/mmHg) were not different (p>0.05) between control and SMTC conditions.  SMTC 
reduced (p<0.05) blood flow and VC at rest and during exercise in the kidneys, adrenals, and 
liver.  These results enhance our understanding of the role of NO-mediated circulatory control by 
demonstrating that nNOS does not appear to subserve an obligatory role in the exercising muscle 
hyperemic response in the rat. 
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 Introduction 
Nitric oxide (NO) is a low molecular-weight, highly diffusible signaling molecule 
synthesized through the conversion of L-arginine to L-citrulline via the calcium dependent 
enzyme NO synthase (NOS).  In healthy subjects, NO derived from two constitutively expressed 
NOS isoforms, neuronal NOS (nNOS) and endothelial NOS (eNOS), exerts influences on a vast 
array of biological functions including, for example, the regulation of vascular control, 
facilitation of skeletal muscle glucose uptake, modulation of muscle contractile function, and 
myoblast differentiation (40).  Specifically in regards to vascular control, experimental 
pharmacological non-selective NOS inhibition in human and animal models provides the 
foundation for a substantial body of evidence that NO plays integral roles in regulating blood 
flow in skeletal muscle at rest and during exercise (20, 32) the kidney (16) and splanchnic organs 
(12). 
One consequence of non-selective NOS inhibition is the inability to differentiate the 
specific NOS isoform origin of vasoactive NO within various vascular beds and physiological 
conditions (i.e., rest or exercise).  Given that vascular endothelial dysfunction commonly 
underlies peripheral circulatory derangements manifested in conditions such as chronic heart 
failure (CHF; 24), diabetes (19), and advancing age (37), NO-mediated circulatory control has 
been ascribed principally to eNOS.  However, the localization of nNOS near the sarcolemmal 
membrane (26) makes nNOS-derived NO a viable candidate in the regulation of the peripheral 
circulation, particularly during exercise.  In this regard, emergent theoretical (21) and empirical 
(15, 26, 38, 39, 42) evidence has identified a more substantial role for nNOS-derived NO in 
vascular smooth muscle and blood flow regulation than considered previously.  For example, 
nNOS-derived NO modulates vascular responses in isolated mouse hindlimb muscle (10, 27) and 
modulates basal (i.e., resting) total forearm (39) and coronary artery (38) blood flow in humans. 
Strong support for the importance of nNOS-derived NO in blood flow regulation is that 
sympathetic vascular modulation is impaired in nNOS deficient skeletal muscle from both mice 
(42, 43) and humans (36).  Consequently, skeletal muscle perfusion during exercise is 
compromised in nNOS deficient mice (26).  However, to our knowledge obligatory participation 
of nNOS-derived NO in the hyperemic response to active locomotor skeletal muscle in healthy 
14 
 
individuals during physiologic exercise has not been investigated.  Given that many clinical 
populations are hallmarked by skeletal muscle blood flow decrements and resultant exercise 
intolerance, resolution of this issue would constitute a fundamental step in the development of 
pharmacological and non-pharmacological interventions to mitigate vascular dysfunction in 
affected individuals.   
The aim of the present study was to investigate the effects of nNOS inhibition via the 
selective nNOS blocker S-methyl-L-thiocitrulline (SMTC; 9, 44) on total and inter- and 
intramuscular hindlimb, kidney, and splanchnic organ blood flow and vascular conductance 
(VC) at rest and during submaximal dynamic treadmill exercise in healthy rats.  Based on the 
evidence summarized above regarding the role of nNOS in peripheral circulatory control we 
hypothesized that nNOS inhibition would significantly reduce blood flow and VC to these 
tissues at rest and during exercise. 
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 Methods 
Animal selection and assignment 
 A total of 19 young adult (age: 4-6 months) male Sprague-Dawley rats (body weight: 
555±23 g) were utilized.  All animals were purchased from Charles River Laboratories 
(Wilmington, MA, USA) and, upon arrival at Kansas State University, were housed in approved 
facilities and maintained on a 12:12 hour light-dark cycle with food and water available ad 
libitum.  All experimental procedures described herein were conducted according to the 
guidelines established by the Journal of Physiology (7) and the National Institutes of Health and 
were approved by Kansas State University’s Institutional Animal Care and Use Committee.  
Initially, rats were assigned randomly to either a rest (n=9) or exercise (n=6) group with 4 
additional rats added to the exercise group to increase statistical power.  Prior to the initiation of 
the experimental protocol, the exercise group was familiarized with running on a custom-built 
motor-driven treadmill over a ~2 week period in which rats ran for ~5 min/day at a speed of 20 
m/min up a 10% grade. 
 
Surgical procedure 
   On the day of data collection, animals were anesthetized with 5% isoflurane.  
Subsequently, while being maintained on a 2-3% isoflurane-oxygen mixture, one catheter (PE-10 
connected to PE-50, Clay Adams Brand, Sparks, MD, USA) was placed in the ascending aorta 
via the right carotid artery and a second was placed in the caudal (tail) artery, as described 
previously (31).  Both catheters were tunneled subcutaneously to the dorsal aspect of the cervical 
region, exteriorized through a puncture wound in the skin, and incisions were closed.  Anesthesia 
was then terminated and the animal was given 1-2 hours to recover prior to the initiation of the 
final experimental protocol (Figure 2.1). 
 
Rest (n=9) 
 Following recovery, the tail artery catheter was attached to a pressure transducer (Gould 
Statham P23ID, Valley View, OH, USA) which was connected to a recorder and 10 µg/kg of 
acetylcholine (ACh: Sigma Chemical, St. Louis, MO, USA) was injected via the carotid artery 
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catheter.  The subsequent peak hypotensive response to ACh injections was measured and 
recorded.  Following the normalization of mean arterial pressure (MAP), the tail artery catheter 
was connected to a 1 ml syringe and blood withdrawal was initiated at a rate of 0.25 ml/min via a 
Harvard infusion/withdrawal pump (model 907, Cambridge, MA, USA).  Simultaneously, heart 
rate (HR) and MAP were measured and recorded via the carotid artery catheter for ~10 s.  
Immediately after the HR and MAP recording, the carotid artery catheter was disconnected from 
the pressure transducer and 0.5-0.6x10
6
 15 µm diameter microspheres (
85
Sr or 
46
Sc in random 
order: Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) were injected into the 
aortic arch to determine regional blood flows. 
 Following the initial microsphere injection, the animal remained in the resting condition 
for ~10 minutes after which 2.1±0.1 µmol/kg of SMTC (Sigma, St. Louis, MO, USA), an nNOS 
inhibitor with a 17-fold selectivity for nNOS over eNOS (9), dissolved in 1.2 ml of saline was 
infused into the tail artery catheter for 6 min.  This dose of SMTC was selected based on 
previous investigations in which similar doses were used to inhibit nNOS (15, 38, 39, 44) and 
preliminary studies in our laboratory where we examined the highest possible SMTC dose that 
could be administered without affecting the hypotensive responses to ACh (Copp, Hirai, 
Schwagerl, Musch, Poole, unpublished observations).  Once the infusion was complete, a second 
microsphere injection (differently labeled from the first injection) followed by a second ACh 
injection protocol were performed exactly as described above.  Subsequent to the recovery of 
MAP after the second ACh injection (~5 min), 10 mg/kg of the non-selective NOS inhibitor N
G
-
nitro-L-arginine-methyl-ester (L-NAME: Sigma Chemical, St. Louis, MO, USA) was 
administered into the carotid artery catheter and HR and MAP were monitored for 5 minutes.  A 
third injection of 10 µg/kg of ACh was then performed and the hypotensive response was again 
measured. 
 
Exercise (n=10) 
 Each rat was placed initially on the treadmill and, after a period of stabilization (~2 hours 
after instrumentation), 10 µg/kg of ACh was injected into carotid artery catheter.  The peak 
hypotensive response was measured and recorded from the tail artery catheter.  After the 
injection, the tail artery catheter was connected to a 1 ml plastic syringe and the Harvard 
infusion/withdrawal pump. Exercise was initiated, and the speed of the treadmill increased 
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progressively over the next 30 s to a speed of 20 m/min (10% grade) which has been 
demonstrated previously to elicit ~55-65% of peak O2 uptake ( peakOV 2
 ; 29).  The rat was then 
exercised steadily and after ~3.5 min of total exercise time, blood withdrawal from the tail artery 
catheter was initiated at a rate of 0.25 ml/min.  HR and MAP were measured simultaneously and 
recorded via the carotid artery catheter for ~10 s.  Immediately afterwards, the carotid artery 
catheter was disconnected from the pressure transducer and 0.5-0.6x10
6
 microspheres (
85
Sr or 
46
Sc in random order) were injected into the aortic arch.  Approximately 15-30 seconds after 
microsphere injection, exercise was terminated and each rat was allowed a minimum of 30 min 
to recover.   
 After recovery from this exercise bout, 2.1±0.1 µmol/kg of SMTC dissolved in 1.2 ml of 
saline was infused via the tail catheter over a 6 min period.  Following the infusion, the tail 
catheter was re-connected to a syringe and the Harvard pump for blood withdrawal.  The second 
bout of exercise, microsphere injection (differently labeled from the first run), and ACh injection 
protocols were performed exactly as described above for the control (non-SMTC infusion) 
condition.  Following recovery from the second ACh injection and as described at rest, L-NAME 
was administered and MAP and HR were monitored for 5 min.  Subsequently, a third ACh 
injection was performed.  The hypotensive responses from the rest and exercise groups were 
combined and the responses were then compared among conditions in order to determine the 
efficacy of selective (SMTC) and non-selective NOS inhibition (L-NAME). 
 
Determination of blood flow and vascular conductance  
 Following the final (third) ACh injection, each animal was euthanized by means of 
pentobarbital overdose administered via the carotid artery catheter.  The thorax was opened, and 
placement of the carotid artery catheter into the aortic arch was confirmed by anatomical 
dissection.  Organs of the splanchnic region, the kidneys, and principal locomotor muscles of 
both hindlimbs were identified and removed.  The tissues were blotted, weighed, and placed 
immediately into counting vials. 
 The radioactivity of each tissue was determined on a gamma scintillation counter 
(Packard Auto Gamma Spectrometer, model 5230, Downers Grove, IL, USA).  Accounting for 
cross-talk between isotopes (
46
Sc and
 85
Sr), blood flows to each tissue were determined using the 
reference sample method (31) and expressed as milliliters per minute per 100 g of tissue 
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(ml/min/100g).  Adequate mixing of the microspheres was verified for each injection by 
demonstrating a <15% difference between blood flow to the right and left kidneys and/or to the 
right and left hindquarter musculature.  All blood flow data were normalized to the MAP 
measured immediately prior to the microsphere injection and expressed as VC 
(ml/min/100g/mmHg).   
 
Statistical analyses 
 Resting HR and MAP values as well as the hypotensive responses to ACh from the 
resting and exercising experimental groups were combined (n=19) and compared among 
conditions (pre- and post-SMTC and post-L-NAME) via repeated measures one-way ANOVA.  
Where significant differences were found a Student-Newman-Keuls post-hoc test was used to 
determine where differences existed.  In the exercising group, HR and MAP measured during the 
two exercise bouts were compared via paired Student’s t-tests.  Muscle blood flows and tissue 
VCs measured either at rest or during exercise before and after SMTC administration were 
compared using paired two-tailed Student’s t-tests.  Pearson product moment correlations were 
performed to determine whether the absolute and relative reductions in resting blood flow (Δ 
blood flow) and VC (Δ VC) in the individual muscles or muscle parts of the hindlimb produced 
by SMTC administration were correlated with their estimated fiber type composition and/or 
relative blood flow and VC during the control condition.  The fiber type composition of each 
muscle or muscle part was based on the percentage of type I and IIa fibers in the individual 
muscles and muscle parts of the rat hindlimb as described by Delp and Duan (4).  Results are 
presented as mean±SEM.  Significance was accepted at p<0.05. 
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 Results 
Effects of SMTC on hindlimb muscle(s) blood flow and vascular conductance 
Total resting hindlimb muscle blood flow (control: 20±2, SMTC: 12±2 ml/min/100g, 
p<0.05) and VC (control: 0.16±0.02, SMTC: 0.09±0.01 ml/min/100g/mmHg, p<0.05) were 
reduced following SMTC administration (Figure 2.1).  Specifically, blood flow was significantly 
reduced in 8 of 24 individual muscles or muscle parts whereas VC was reduced in 13 of 24 of 
these tissues (Table 2.1).  The absolute Δ blood flow and Δ VC after SMTC were significantly 
correlated with the percent sum of type I and IIa fibers found in the individual muscles or muscle 
parts (Δ blood flow: r=0.85, Δ VC: r=0.87, p<0.001 for both, Figure 2.2) such that the greatest 
effect of SMTC administration occurred in those muscles or muscle parts containing primarily 
oxidative muscle fibers.  There were no significant correlations between the relative Δ blood 
flow and Δ VC after SMTC administration and the percent sum of type I and IIa muscle fibers in 
the individual tissues examined.  The absolute Δ blood flow and Δ VC after SMTC increased as 
a function of the relative resting blood flow (r=0.97, p<0.001) and VC (r=0.95, p<0.001) under 
control conditions, respectively, to the individual muscles or muscle parts of hindlimb (Figure 
2.3). 
 In marked contrast to the resting condition, total hindlimb muscle blood flow (control: 
108±7, SMTC: 105±8 ml/min/100g, p>0.05) and VC (control: 0.77±0.06; SMTC: 0.70±0.05 
ml/min/100g/mmHg, p>0.05) during exercise were not different between control and SMTC 
conditions (Figure 2.1).  Moreover, blood flow and VC were not reduced (p>0.05) in any of the 
24 individual muscles or muscle parts of the hindlimb musculature. 
 
Effects of SMTC on kidney and splanchnic organ blood flow 
 During both rest and exercise SMTC administration reduced (p<0.05) blood flow and VC 
in the right and left kidney, adrenal glands, and liver but not in the small or large intestine, 
pancreas, spleen or stomach (Table 2.2). 
 
Effects of SMTC and L-NAME on MAP, HR, and hypotensive response to ACh injections 
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 The effects of SMTC and L-NAME administration on resting and exercising MAP and 
HR are presented in Figure 2.4.  At rest, SMTC increased MAP and reduced HR compared to the 
control condition.  The administration of L-NAME further elevated MAP and decreased HR such 
that the values attained were significantly different (p<0.05) from both the control and SMTC 
conditions.  In the exercising rats, MAP and HR measured during exercise immediately prior to 
microsphere injection were elevated above resting values in the control condition, whereas after 
SMTC administration exercising HR was significantly elevated (p<0.05) above rest but MAP 
was not.  More importantly, the MAP and HR measured during exercise were not different 
between control and SMTC conditions. 
The absolute and relative hypotensive responses (Δ MAP) to ACh injection are presented 
in Figure 2.5.  The absolute Δ MAP was increased after SMTC administration compared to 
control whereas after L-NAME it was reduced compared to SMTC but not control.  Conversely, 
there were no differences in the relative Δ MAP after ACh injections between control and SMTC 
conditions and L-NAME resulted in significant blunting of relative Δ MAP compared to both 
control and SMTC. 
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 Discussion 
The present investigation is the first of its kind to investigate systematically the effects of 
selective nNOS inhibition on inter- and intramuscular hindlimb muscle(s) blood flow at rest and 
during submaximal treadmill exercise in the conscious rat.  Consistent with our hypothesis, total 
hindlimb muscle blood flow and VC were reduced at rest after SMTC.  The absolute, but not 
relative, Δ blood flow and Δ VC to the individual tissues after nNOS inhibition were correlated 
with muscle fiber-type such that the greatest reductions occurred in individual muscles and 
muscle parts with the greatest proportion of oxidative fibers.  However, contrary to our 
hypothesis there was no effect of nNOS inhibition on exercising blood flow or VC in the total 
hindlimb or any of the individual muscles or muscle parts.  In addition, nNOS inhibition reduced 
right and left kidney, adrenal and liver blood flow both at rest and during exercise. The present 
study demonstrates that nNOS-derived NO plays an integral role in regulating basal (i.e., resting) 
locomotory skeletal muscle blood flow but appears not to be obligatory for achieving the 
exercise hyperemic response, at least during these submaximal running speeds (equivalent to 
~55-65% of peakOV 2
 ) in the rat.  
 
Relationship with the literature 
 Presently, we found that SMTC administration reduced resting total hindlimb muscle 
blood flow and VC by 38% and 47%, respectively.  These results are consistent with recent 
reports from Seddon and colleagues of 30% (39) and 36% (38) SMTC-induced blood flow 
reductions in the human forearm.  In those same investigations from Seddon et al. infusion of the 
non-selective NOS inhibitor N
G
-monomethyl-L-arginine (L-NMMA) reduced blood flow by 
only marginally higher values of 37% (39) and 40% (38), respectively.  Taken together, these 
data suggest that at rest nNOS may supply the bulk of the NO-mediated blood flow regulatory 
signal (38, 39).  Furthermore, our data demonstrate that within the hindlimb musculature the 
greatest reductions in resting blood flow and VC occurred in the muscles composed of primarily 
oxidative muscle fibers.  This was somewhat surprising given that previous in vitro (33) and 
histochemical (22) data in rodents suggests that nNOS is the predominant NOS isoform in less-
oxidative fast-twitch muscle but not in more oxidative muscle fibers.  The different implications 
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from those reports and our current study are likely due to our ability to measure specifically 
blood flow within an intact physiological model.  For example, we demonstrate a strong 
correlation between the Δ blood flow and VC after SMTC and the relative blood flow and VC, 
respectively, measured during control conditions (Figure 2.4).  This may indicate that it is not 
fiber-type composition per se, but rather the relatively high resting muscle blood flows and VCs 
that drive the effects of SMTC in the primarily oxidative muscles.    
 Previously, our laboratory has utilized the conscious rat model of treadmill exercise in the 
presence of the non-selective NOS inhibitor L-NAME to demonstrate that NO plays an 
important role in the regulation of hindlimb muscle blood flow during locomotory exercise (3, 
12, 30). While those studies and others using non-selective NOS inhibition cannot identify the 
specific isoform from which the NO originates, eNOS-derived NO has traditionally been 
considered to be responsible for most, if not all, of the NO response.  However, evidence in 
contracting mouse (8, 10, 42) and human (36) muscle in which nNOS is absent provides support 
for nNOS-derived NO as a key component in NO-mediated blood flow control during muscle 
contractions.  Specifically, in healthy subjects, nNOS-derived NO attenuates norepinephrine-
induced vasoconstriction in active muscle vascular beds whereas this sympathetic modulation is 
absent in skeletal muscle that lacks nNOS (36, 42).  More recently, novel work in transgenic mdx 
mice (a model of Duchenne muscular dystrophy with transplanted nNOS anchoring proteins) 
indicates that these animals have greater active locomotor muscle blood flow and thus enhanced 
treadmill exercise performance compared to their non-transgenic mdx counterparts (2, 26).  
While these observations have important clinical significance for a variety of chronic 
pathological conditions in which nNOS structure or function is altered, our current study is the 
first to test the hypothesis that, during physiological exercise nNOS-derived NO contributes to 
the regulation of active muscle blood flow in healthy individuals.  However, contrary to our 
hypothesis, our data demonstrate that nNOS inhibition does not alter the hyperemic response to 
exercise. 
The control of blood flow within active skeletal muscle is hallmarked by substantial 
redundancy and synergy (14).  For example, when one NOS isoform is chronically disrupted 
(i.e., eNOS or nNOS knockout models) compensatory mechanisms may increase NO production 
from existing isoforms (1, 21, 41).  Additionally, there is evidence that NO is not the sole 
mediator of sympathetic modulation within active skeletal muscle vascular beds (5, 6, 35) and 
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the roles of other substances may increase when nNOS is inhibited.  Until any such redundancy 
of the NO sympathetic-inhibitory and/or vasodilatory signal in healthy subjects is dissected 
systematically, it may be inappropriate to conclude that NO derived from nNOS does not 
contribute to locomotor skeletal muscle blood flow regulation during exercise under normal 
physiological conditions (i.e., in the absence of SMTC administration).  Rather, the present 
investigation indicates that nNOS participation may not be obligatory for the exercise hyperemic 
response. 
At rest, the splanchnic and renal circulations may account for nearly 50% of the total 
cardiac output and thus serve as important controllers of MAP and constitute a vast blood 
volume reservoir for the active skeletal muscle to draw upon during dynamic exercise (17).  
Previous investigations have indicated that NO is an important blood flow regulator in these 
circulations (15, 34).  The present investigation identifies nNOS-derived NO as an important 
mediator of kidney, adrenal and liver blood flow at rest and during exercise which is consistent 
with in vitro (18) and anesthetized (45) rodent models after SMTC administration.  The ~35% 
reduction in liver blood flow and VC found herein is in agreement with the presence of nNOS in 
the liver vasculature of the rat (28).  However, it is important to note that the human liver is 
thought to lack nNOS (25).  Collectively, the literature supports a crucial role of nNOS in the 
regulation of the kidney, adrenal, and liver circulations and, accordingly, diseases affecting these 
circulations have been associated with impaired nNOS function (23, 34). 
 
Experimental considerations 
 The interpretation of the present results depends highly on the efficacy of the current dose 
of SMTC (2.1±0.1 µmol/kg or 0.56±0.02 mg/kg) to block nNOS without affecting eNOS-
mediated function.  We believe that the selected dose was appropriate for the following reasons: 
First, the SMTC dose utilized presently was selected based on previous investigations in rats 
reporting selective nNOS inhibition with SMTC in vivo (15, 42, 44) and preliminary studies from 
our laboratory which attempted to elucidate the highest SMTC dose that did not affect 
endothelial-mediated NO function (Copp, Hirai, Schwagerl, Musch, Poole, unpublished 
observations).  Indeed, the SMTC dose utilized in the present investigation is slightly greater 
than the highest in vivo doses of SMTC that achieved selective nNOS inhibition in rats reported 
by Wakefield et al. (44, 0.3 mg/kg) and Komers et al. (23, 0.5 mg/kg).  Second, it is important to 
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note the similar reductions in blood flow and VC observed in the kidneys, adrenals and liver both 
at rest and during exercise.  This suggests that the SMTC dose was sufficient to inhibit nNOS 
under both conditions and the lack of an effect observed during exercise in the hindlimb 
musculature results from the obligatory role of nNOS-derived NO at rest but not during exercise.  
Third, to confirm that the SMTC dose utilized presently did not affect endothelial-mediated NO 
function we examined the hypotensive responses to ACh injections before and after SMTC and 
after L-NAME administration (which is expected to inhibit endothelial-mediated vasodilation).  
We considered that if SMTC did not affect eNOS function the hypotensive response to ACh 
would not be attenuated when compared to control conditions.  Conversely, we anticipated that 
eNOS function and, therefore, the hypotensive response to ACh would be attenuated after L-
NAME.  As anticipated, SMTC did not attenuate the absolute or relative hypotensive responses 
to ACh compared to control.  Furthermore, the absolute hypotensive response after L-NAME 
was attenuated compared to SMTC but not control and the relative hypotensive response was 
attenuated compared to both control and SMTC conditions.  Taking into account the primary 
comparison of interest (control vs. SMTC) and the considerations presented above, our results 
support that SMTC administration in the present study effectively inhibited nNOS but did not 
inhibit eNOS.   
NO has many diverse roles in intact biological systems.  For example, NO derived from 
nNOS has been implicated in the metabolic inhibition of sympathetically-mediated 
vasoconstriction (i.e., functional sympatholysis; 11) as well as regulation of regional sympathetic 
nerve activity (13), the modulation of skeletal muscle force production (10), and the direct 
relaxation of vascular smooth muscle .  Given that the same absolute treadmill speed was utilized 
before and after SMTC, the power output necessary to sustain running was the same during the 
two exercise bouts.  Therefore, muscle force production likely changed little, if at all, between 
control and SMTC conditions.  In addition, given that SMTC increased MAP at rest we report 
both resting blood flow and VC.  The fact that SMTC reduced blood flow and VC at rest 
provides convincing evidence that nNOS-derived NO is an obligatory controller of local resting 
muscle perfusion.  However, the present in vivo model does not allow for the determination of 
the specific mechanisms by which bioavailable nNOS-derived NO exerts its influence on the 
regulation of blood flow and VC.  Notwithstanding this model limitation, a major strength of the 
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present study is that it presents the first evaluation of the effects of selective nNOS inhibition on 
circulatory control in a healthy, intact biological system performing locomotory exercise.   
 
Summary and conclusions 
 This study investigated the effects of selective nNOS inhibition via SMTC on hindlimb 
muscle(s) blood flow and VC at rest and during submaximal treadmill exercise in the healthy 
conscious rat.  We have identified that nNOS inhibition reduces blood flow and VC in the 
skeletal muscle of the hindlimb at rest, however, nNOS inhibition had no effect on hindlimb 
musculature blood flow and VC during exercise.  These results enhance our understanding of the 
role of nNOS in circulatory control by demonstrating that nNOS-derived NO is not obligatory 
for achieving the hyperemic response in healthy rats performing whole-body dynamic exercise. 
Moreover, our data may be directly relevant to a growing number of clinical populations in 
which impaired vascular control and reduced NO bioavailability are hallmarks of disease 
pathology. 
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Table 2.1. Effects of nNOS inhibition on resting skeletal muscle blood flow and VC 
 Blood flow  Vascular conductance 
 Control SMTC  Control SMTC 
Ankle extensors      
Soleus 87±14 46±8*  0.70 ± 0.11 0.38 ± 0.07* 
Plantaris 17±3 12 ± 4  0.13 ± 0.02 0.08 ± 0.02 
Red gastrocnemius 51 ± 12 20 ± 6*  0.40 ± 0.09 0.15 ± 0.03* 
White gastrocnemius 15 ± 2 9 ± 2*  0.12 ± 0.01 0.07 ± 0.02* 
Mixed gastrocnemius 19 ± 4 9 ± 2*  0.15 ± 0.03 0.06 ± 0.01* 
Tibialis posterior 28 ± 7 14 ± 4  0.22 ± 0.05 0.10 ± 0.03* 
Flexor digitorum longus 50 ± 11 32 ± 15  0.40 ± 0.09 0.21 ± 0.11 
Flexor halicus longus 19 ± 3 10 ± 3*  0.15 ± 0.02 0.07 ± 0.02* 
      
Ankle flexors      
Tibialis anterior, red 64 ± 9 35 ± 14  0.50 ± 0.06 0.31 ± 0.04 
Tibialis anterior, white 23 ± 3 16 ± 4  0.18 ± 0.02 0.13 ± 0.03 
Extensor digitorum longus 21 ± 3 14 ± 5  0.16 ± 0.02 0.09 ± 0.03 
Peroneals 25 ± 5 12 ± 4  0.20 ± 0.05 0.08 ± 0.02* 
      
Knee extensors      
Vastus intermedius 83 ± 13 46 ± 9*  0.65 ± 0.09 0.34 ± 0.06* 
Vastus medialis 14 ± 3 11 ± 2  0.11 ± 0.02 0.08 ± 0.01 
Vastus lateralis, red 73 ± 14 41 ± 14  0.57 ± 0.10 0.33 ± 0.12 
Vastus lateralis, white 9 ± 1 9 ± 2  0.07 ± 0.01 0.06 ± 0.01 
Vastus lateralis, mixed 19 ± 3 15 ± 3  0.15 ± 0.02 0.10 ± 0.02 
Rectus femoris, red 54 ± 14 18 ± 6*  0.42 ± 0.10 0.14 ± 0.04* 
Rectus femoris, white 16 ± 2 13 ± 3  0.12 ± 0.01 0.09 ± 0.02 
      
Knee flexors      
Biceps femoris anterior 11 ± 1 8 ± 1  0.09 ± 0.01 0.06 ± 0.01* 
Biceps femoris posterior 18 ±  3 10 ± 2  0.14 ± 0.03 0.07 ± 0.01* 
Semitendinosus 20 ± 3 10 ± 2*  0.16 ± 0.03 0.07 ± 0.01* 
Semimembranosus, red 14 ± 1 11 ± 2  0.11 ± 0.01 0.07 ± 0.01* 
Semimembranosus, white 9 ± 1 8 ± 1  0.07 ± 0.01 0.06 ± 0.01 
 
Effects of SMTC (2.1±0.1 µmol/kg) on resting blood flow (ml/min/100g) and vascular 
conductance (ml/min/100g/mmHg) to the individual muscles or muscle parts of the rat hindlimb. 
Data are mean±SEM.  n=9, *p<0.05 versus control. 
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Table 2.2. Effects of nNOS inhibition on kidney and splanchnic organ blood flow and VC 
 At rest  During exercise 
 Control SMTC  Control SMTC 
Blood flow      
     Right kidney 871±92 514±45*  666±74 452±30* 
     Left kidney 880±101 499±65*  666±79 431±31* 
     Stomach 137±24 111±20  71±12 61±12 
     Adrenals 736±103 443±74*  653±85 261±25* 
     Spleen 269±32 310±30  60± 14 73±19 
     Pancreas 240±42 180±29  132± 27 85±20 
     Sm. intestine 539±80 502±76  366± 60 395±55 
     Lg. intestine 309±43 287±34  194± 44 179±43 
     Liver 26±3 17±3*  30± 8 11±1* 
      
VC      
     Right kidney 6.92±0.68 3.89±0.40*  4.73±0.60 3.03±0.18* 
     Left kidney 6.98±0.73 3.71±0.50*  4.75±0.67 2.90±0.20* 
     Stomach 1.08±0.18 0.80±0.16  0.51±0.10 0.42±0.09 
     Adrenals 6.35±0.60 3.71±0.68*  4.64±0.69 1.77±0.19* 
     Spleen 2.13±0.26 2.21±0.26  0.43±0.10 0.49±0.12 
     Pancreas 1.88±0.31 1.35±0.21  0.94±0.19 0.60±0.15 
     Sm. intestine 4.24±0.58 4.09±0.55  2.61±0.45 2.66±0.38 
     Lg. intestine 2.47±0.35 2.19±0.25  1.71±0.28 1.42±0.21 
     Liver 0.22±0.02 0.14±0.03*  0.21±0.06 0.07±0.01* 
 
Effects of SMTC (2.1±0.1 µmol/kg) on resting (n=9) and exercising (n=10) blood flow 
(ml/min
/
100g) and vascular conductance (ml/min/100g/mmHg) to the kidneys and organs of the 
splanchnic region. Data are mean±SEM.  *p<0.05 versus control. 
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Figure 2.1. Effects of nNOS inhibition on resting skeletal muscle blood flow and VC 
 
Effects of SMTC (2.1±0.1 µmol/kg) on resting total hindlimb blood flow and vascular 
conductance (VC).  Individual animals and group means±SEM are shown.  n=9, *p<0.05 vs. 
control. 
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Figure 2.2. Relationships between changes in resting blood flow and VC following SMTC 
and muscle fiber-type composition 
 
 
Correlations between the percent sum of type I and IIa fibers in the individual muscles and 
muscle parts of the rat hindlimb and the absolute changes in resting blood flow (Δ blood flow) 
and vascular conductance (Δ VC) after SMTC infusion (2.1±0.1 µmol/kg). 
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Figure 2.3. Relationships between resting blood flow and VC and the changes in resting 
blood flow and VC 
 
 
Correlations between the relative resting blood flow and vascular conductance (VC) to the 
individual muscles or muscle parts of the rat hindlimb and the absolute change in relative resting 
blood flow (Δ blood flow) and VC (Δ VC) after SMTC infusion (2.1±0.1 µmol/kg). 
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Figure 2.4. Effects of nNOS inhibition on exercising skeletal muscle blood flow and VC 
 
Effects of SMTC (2.1±0.1 µmol/kg) on exercising total hindlimb blood flow and vascular 
conductance (VC).  Individual animals and group means±SEM are shown.  n=9.  There were no 
significant differences between control and SMTC. 
 
32 
 
Figure 2.5. Effects of nNOS inhibition on resting and exercising MAP and HR 
 
Mean arterial pressure (MAP, top panel) and heart rate (HR, bottom panel) during control and 
after SMTC (2.1±0.1 µmol/kg) and L-NAME (10 mg/kg) administration.  Rest: n=19, Exercise: 
n=10, *p<0.05 vs. control, 
†
p< 0.05 vs. SMTC, 
#
p<0.05 vs. same condition at rest. 
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Figure 2.6. Effects of SMTC and L-NAME on the hypotensive response to ACh 
 
Absolute and relative hypotensive responses to acetylcholine injection (10 μg/kg) for control 
condition and after SMTC (2.1±0.1 µmol/kg) and L-NAME (10 mg/kg) administration.  n=19, 
*p<0.05 vs. control, 
†
p<0.05 vs. SMTC. 
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Chapter 3 - Muscle fiber-type dependence of neuronal nitric oxide 
synthase-mediated vascular control in the rat during high-speed 
treadmill running 
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 Summary 
Nitric oxide (NO) derived from neuronal NO synthase (nNOS) does not contribute to the 
hyperemic response within rat hindlimb skeletal muscle during low-speed treadmill running.  
This may be attributed to low exercise intensities recruiting primarily oxidative muscle and that 
vascular effects of nNOS-derived NO are manifest principally within glycolytic muscle.  We 
tested the hypothesis that selective nNOS inhibition via S-methyl-L-thiocitrulline (SMTC) would 
reduce rat hindlimb skeletal muscle blood flow and vascular conductance (VC) during high-
speed treadmill running above critical speed (asymptote of the hyperbolic speed versus time-to-
exhaustion relationship for high-speed running and an important glycolytic fast-twitch fiber 
recruitment boundary in the rat) principally within glycolytic fast-twitch muscle.  6 rats 
performed 3 high speed treadmill runs to exhaustion to determine critical speed.  Subsequently, 
hindlimb skeletal muscle blood flow (radiolabelled microspheres) and VC (blood flow/mean 
arterial pressure) were determined during supra-critical speed treadmill running (critical 
speed+15%, 52.5±1.3 m/min) before (control) and after selective nNOS inhibition with 0.56 
mg/kg SMTC.  SMTC reduced total hindlimb skeletal muscle blood flow (control: 241±23, 
SMTC: 204±13 ml/min/100g, p<0.05) and VC (control: 1.88±0.20, SMTC: 1.48±0.13 
ml/min/100g/mmHg, p<0.05) during high-speed running.  The relative reductions in blood flow 
and VC were greater in the highly glycolytic muscles and muscle parts consisting of 100% type 
IIb+d/x fibers compared to the highly oxidative muscles and muscle parts consisting of ≤35% 
type IIb+d/x muscle fibers (p<0.05).  These results extend our understanding of vascular control 
during exercise by identifying fiber-type selective peripheral vascular effects of nNOS-derived 
NO during high-speed treadmill running. 
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 Introduction 
The ability of the cardiovascular system to increase skeletal muscle blood flow and, 
therefore, O2 delivery during exercise is accomplished via neurohumoral activation (to increase 
cardiac output and initiate blood flow redistribution) and local mechanical and vasomotor control 
mechanisms (19).  The robust active muscle blood flow response supports sustained exercise 
performance whereas many disease processes are hallmarked by O2 delivery impairment and 
exercise intolerance (e.g., heart failure, 30). 
 Nitric oxide (NO) is an important cardiovascular signaling molecule that has been 
reported to play an integral role in promoting exercise hyperemia in animals (17, 20) and humans 
(33).  In healthy subjects NO is synthesized enzymatically via neuronal NO synthase (nNOS or 
type I NOS) or endothelial NO synthase (eNOS or type III NOS).  The vasodilatory contributions 
of eNOS-derived NO secondary, at least in part, to vascular endothelial shear stress during 
exercise are well known (15).  The peripheral vascular effects of nNOS-derived NO, particularly 
during dynamic exercise, remain controversial.  For example, our laboratory reported recently 
that acute administration of the selective nNOS inhibitor S-methyl-L-thiocitrulline (SMTC) 
reduced rat hindlimb skeletal muscle blood flow at rest but not during low-speed treadmill 
running (6).  Conversely, nNOS-derived NO attenuates skeletal muscle sympathetic 
vasoconstriction during muscle contractions in both rats (39, 40) and humans (32).  Importantly, 
this “functional sympatholysis” may occur within glycolytic but not oxidative skeletal muscle 
and at high contraction intensities only (38).  The fiber-type and contraction-intensity dependent 
vascular effects of nNOS-derived NO may account for the unchanged skeletal muscle blood flow 
following nNOS inhibition during low-speed treadmill running (6) which recruits primarily 
oxidative slow- and fast-twitch muscle (13, 23).  It is possible that high-speed treadmill running 
which additively recruits highly glycolytic fast-twitch muscle may unmask obligatory nNOS-
derived NO vasomotor control during dynamic exercise.  This information would have important 
implications for diseased (3, e.g., heart failure, 41) and aged (16) populations which have been 
associated with impaired nNOS-mediated function. 
Our laboratory has demonstrated recently that critical speed (the asymptote of the 
hyperbolic speed versus time-to-exhaustion relationship for high-speed running) can be 
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determined empirically in the rat and that running above, relative to below, critical speed recruits 
glycolytic fast-twitch muscle to a greater extent than oxidative slow- and fast-twitch muscle (5).  
In this regard, the ability to accurately measure blood flow distribution among and within active 
skeletal muscles during high-speed running (1, 26) specifically above critical speed (5) makes 
the rat an ideal model to examine the fiber-type dependency of nNOS-mediated vascular control 
during exercise.  Therefore, the present investigation tested the hypothesis that selective nNOS 
inhibition with S-methyl-L-thiocitrulline (SMTC) would reduce rat hindlimb skeletal muscle 
blood flow and (vascular conductance) VC during treadmill running above critical speed whereas 
there would be no effects of SMTC during low-speed treadmill running.  Furthermore, we 
hypothesized that during supra-critical speed running the greatest relative reductions in blood 
flow and VC would occur principally within the muscles and muscle parts composed of highly 
glycolytic type IIb and d/x fibers. 
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 Methods 
Ethical approval 
 The experimental procedures described in the present investigation were approved by the 
Institutional Animal Care and Use Committee of Kansas State University and were conducted 
according the animal use guidelines mandated by The Journal of Physiology (8). 
A total of 17 male Sprague-Dawley rats (~4 months old, body mass 387±13 g, Charles 
River Laboratories, Wilmington, MA, USA) were utilized in the present investigation.  Rats 
were housed 2 per cage in accredited facilities (Association for the Assessment and 
Accreditation of Laboratory Animal Care) with food and water provided ad libitum.  12 rats were 
assigned initially to either the high-speed (n=6) or low-speed (n=6) group and acclimatized to 
running on a custom built motor-driven treadmill over 1 week (5-6 days up to 5 min/day).  The 
treadmill was set to a 5% incline which was maintained throughout the experimental protocol. 
 
Determination of critical speed 
   Rats in the high-speed group performed a peak O2 uptake ( 2OV
 peak) test as described 
previously (25).  Rats performed a progressive ramp-style treadmill test inside a metabolic 
chamber which was placed on the treadmill belt.  Ambient air was drawn through the chamber 
via a vacuum pump (Neptune-Dyna model 4K, Dover, NJ, USA), through drierite (anhydrous 
CaSO4), through a flowmeter (Fischer-Porter model 10A1378, Burr Ridge, IL, USA) and 
delivered subsequently to inline O2 and CO2 analyzers (O2: model S-3A/I, CO2: model CD-3A 
AEI Technologies, Pittsburgh, PA, USA). The speed of the treadmill and corresponding 2OV
  
and 2COV
  were monitored and recorded continuously throughout the test.  The test was 
terminated when the rat was unable or unwilling to keep pace with the treadmill belt. 
Critical speed was determined as described previously (5).  Rats in the high-speed group 
performed at least 3 runs to exhaustion, in random order, at a range of speeds corresponding to 
90-115% of the speed that elicited 2OV
 peak.  For each constant-speed test rats were given a 2 
minute warm-up at 20-25 m/min which was followed by 1 minute of quiet resting.  The treadmill 
speed was then increased rapidly over an ~10 s period to the pre-determined speed.  Rats were 
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encouraged to run by applying manual bursts of high pressure air at the hindlimbs whenever they 
drifted towards the back of the treadmill lane.  Tests were terminated when the rat could not 
maintain pace with the treadmill belt despite obvious exertion.  Time-to-exhaustion was 
measured to the nearest tenth of a second.  The following criteria constituted a successful 
constant-speed test: 1) the ability of the rat to quickly settle into a normal running gait at the 
beginning of the test, 2) a noticeable change in gait (i.e., lowering of the hindquarters and a 
rising of the snout) preceding exhaustion, and 3) marked attenuation of the righting reflex when 
placed in the supine position.  A minimum of 24 hours rest was given between consecutive 
exercise tests.  Following completion of the constant-speed tests, the individual critical speeds 
were determined by 1) the hyperbolic speed-time model (time=D’/(speed-critical speed)) where 
the asymptote of the hyperbolic curve is the critical speed and the curvature constant is D’ and 2) 
the linear 1/time model (speed = D’*1/time+critical speed) where speed is plotted as a function 
of the inverse of time (s)-to-exhaustion and the intercept of the regression line is the critical 
speed and the slope is D’(12).  For both models, D’ (vertical distance in meters) was multiplied 
by the rats’ average weight in kg for the constant-speed tests to determine m-kg, then converted 
to W’ in joules (J) using the relationship: 1 J = 0.103155 m-kg.  Both the hyperbolic and linear 
1/time models were utilized to ensure accuracy and robustness of the critical speed estimation. 
 
Measurement of hindlimb skeletal muscle blood flow 
   On the final experimental day anesthesia was induced with a 5% isoflurane-O2 mixture 
with maintenance on 2-3% isoflurane-O2.  Subsequently, one catheter (PE-10 connected to PE-
50, Clay Adams Brand, Sparks, MD, USA) was placed in the ascending aorta via the right 
carotid artery and a second catheter was placed in the caudal (tail) artery.  The catheters were 
tunneled subcutaneously to the dorsal cervical region and exteriorized through a puncture wound 
in the skin.  Anesthesia was terminated and the animal was given ≥1 hour to recover prior to 
blood flow measurement. 
Following recovery, each rat (high-speed group) was placed on the treadmill and the tail 
artery catheter was connected to a 1 ml plastic syringe and a Harvard infusion/withdrawal pump 
while the carotid artery catheter was connected to a pressure transducer (Gould Statham P23ID, 
Valley View, OH, USA) and chart recorder for continuous monitoring of mean arterial pressure 
(MAP) and heart rate (HR).  Exercise was then initiated and each rat ran at a speed of 25 m/min 
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for 1 min.  At the 1 min mark the speed of the treadmill was increased to the speed equaling 15% 
above each individual rat’s critical speed determined from the linear 1/time model (selected for 
the slightly, but not significantly, higher average critical speed estimation from this model, see 
Results).  After 1.5 minutes of running at this speed (2.5 minutes of total exercise time) blood 
withdrawal from the tail artery catheter was initiated at a rate of 0.25 ml/min while MAP and HR 
were measured and recorded simultaneously via the carotid artery catheter.  The carotid artery 
catheter was then disconnected from the pressure transducer and 0.5-0.6x10
6
 microspheres (
85
Sr 
or 
57
Co in random order, Perkin Elmer, Waltham, MA, USA) were injected via carotid catheter 
into the aortic arch.  Following microsphere injection and while the rat was still running a 0.3 ml 
blood sample was taken from the carotid artery catheter for determination of arterial pH, blood 
gases, and [lactate].  Exercise was then terminated and blood withdrawal from the caudal artery 
catheter (which was occurring simultaneous with microsphere injection) was stopped.  The 
reference blood sample was collected and rats were then given 1 hour to recover. 
 After the 1 hour recovery period, 0.56 mg/kg (dissolved in 0.5 ml of heparinized saline) 
of the selective nNOS inhibitor SMTC (11, 28) was infused as a bolus into the caudal artery 
catheter (see below and Discussion for details regarding assessment of the efficacy and 
selectivity of nNOS inhibition).  The tail catheter was then connected to a 1 ml syringe which 
was placed in the Harvard pump for blood withdrawal.  2 min following SMTC infusion a 
second bout of exercise, microsphere injection (differently labeled from the first run), and blood 
sample collection were performed exactly as described above for the control condition.  ~10-15 
min following exercise cessation the non-selective NOS inhibitor N
G
-arginine-methyl-ester (L-
NAME) was administered and MAP and HR were monitored and recorded for an additional ~10 
min (see below for more details). 
  
Low-speed group 
For rats in the low-speed group MAP, HR and skeletal muscle, kidney, and splanchnic 
organ blood flow were measured before and after nNOS inhibition with SMTC exactly as 
described above for the high-speed group except the treadmill speed was set to 20 m/min for 
both the control and SMTC exercise bouts (i.e., same experimental protocol as ref. 6). 
  
Assessment of efficacy and selectivity of nNOS inhibition with SMTC 
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 To confirm that SMTC was mediating effects via nNOS inhibition (as opposed to some 
unknown/unexpected non-specific effect), MAP was measured in 5 additional rats (instrumented 
as described above) in which drug administration order was reversed such that non-selective 
NOS inhibition with L-NAME preceded SMTC.  We reasoned that if SMTC was indeed acting 
via nNOS inhibition there would be no additional SMTC-induced MAP increase in the presence 
of prior L-NAME administration.  In the rats from the exercise groups the selectivity of SMTC 
for nNOS versus eNOS was assessed via measurement of the hypotensive responses to rapid 
acetylcholine (ACh) infusions (10 µg/kg in 0.2 ml saline into the tail artery catheter) while the 
rats sat quietly on the treadmill belt under control, SMTC, and L-NAME conditions.  The 
magnitude and recovery time of the hypotensive response to ACh was utilized as an index of 
eNOS-mediated function.  The absence of any blunting of the hypotensive response to ACh 
following SMTC was considered consistent with the notion that SMTC did not impact eNOS-
mediated function (see Discussion for more details).  
 
Determination of blood flow and VC  
 Following the experimental protocol each animal was euthanized by pentobarbital 
overdose (≥100 mg/kg) administered via the carotid artery catheter.  The thorax was opened, and 
placement of the carotid artery catheter into the aortic arch was confirmed by anatomical 
dissection.  Organs of the splanchnic region, the kidneys, diaphragm, intercostal muscles, and the 
28 individual muscles and muscle portions of the rat hindlimb were identified and removed.  The 
tissues were blotted, weighed, and placed immediately into counting vials. 
 The radioactivity of each tissue was determined on a gamma scintillation counter 
(Packard Auto Gamma Spectrometer model 5230, Downers Grove, IL, USA).  Accounting for 
cross-talk between isotopes, blood flows to each tissue were determined using the reference 
sample method (27) and expressed as milliliters per minute per 100 g of tissue (ml/min/100g).  
Adequate microsphere mixing was verified for each injection by the demonstration of a <15% 
difference between blood flow to the right and left kidneys and/or to the right and left hindlimb 
musculature.  Blood flows were normalized to the MAP measured immediately preceding 
microsphere injection and expressed as VC (ml/min/100g/mmHg). 
 
Data analyses 
47 
 
All data are presented as mean±SEM.  MAP, HR and ACh responses were compared via 
ANOVAs with Student-Newman-Keuls post hoc tests where appropriate.  Blood flow, VC, and 
blood sample variables were compared with paired Student’s t-tests.  z-tests were used to 
determine when reductions in blood flow and VC were different from zero.  Significance was 
accepted at p<0.05. 
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 Results 
High-speed group 
2OV
 peak and critical speed estimation 
 The average 2OV
 peak was 86±1 ml/kg/min (RER=1.07±0.03) with a peak speed of 
54.4±2.4 m/min.  The times to exhaustion at 90, 100, and 115% of peak speed and the hyperbolic 
and linear 1/time model fits and estimated critical speeds for a representative rat are shown in 
Figure 3.1.  The coefficient of determination (r
2
, hyperbolic: 0.96±0.03, linear 1/time: 0.96±0.02, 
p>0.05), W’ (hyperbolic: 162±67 J, linear: 139±66, p>0.05) and estimated critical speed 
(hyperbolic: 44.0±1.8, linear 1/time: 45.6±1.2 m/min, p>0.05) were not different between 
models.  The average running speed at which blood flow measurements were performed was 
52.5±1.3 m/min (15% above critical speed from the 1/time model). 
  
Effects of SMTC on MAP, HR, and blood sample variables 
At rest, SMTC increased MAP and reduced HR compared to control.  During exercise, 
SMTC increased MAP whereas HR was not different between conditions (Table 3.1).  
Exercising arterial blood pH (control: 7.39±0.02, SMTC: 7.40±0.02), PO2 (control: 85.2±2.1, 
SMTC: 88.3±3.3 mmHg), and [lactate] (control: 6.1±0.4, SMTC: 6.7±0.8 mmol/L) were not 
different (p>0.05 for all) between conditions.  SMTC significantly reduced PCO2 (control: 
21.7±0.8, SMTC: 19.8±0.8 mmHg, p<0.05). 
 
Effects of SMTC on hindlimb skeletal muscle blood flow and VC 
 In marked contrast to low-speed running (see below and also ref. 6), SMTC reduced total 
hindlimb skeletal muscle blood flow and VC during high-speed running above critical speed 
(p<0.05, Figure 3.2).  Specifically, blood flow was reduced in 14, and VC in 22, of the 28 
individual muscles or muscle parts of the rat hindlimb (Table 3.2).  Reductions in blood flow and 
VC were found in some muscles across the spectrum of oxidative capacities and muscle fiber-
type compositions.  However, the relative reductions in blood flow and VC following SMTC 
were greater in the highly glycolytic (100% type IIb+d/x fibers, n=5) compared to the highly 
oxidative (≤35% type IIb+d/x fibers, n=5, Figure 3.3) muscles and muscle portions.  Moreover, 
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note in Figure 4.4 that within representative individual muscles containing distinct red and white 
portions the relative reductions in blood flow and VC following SMTC were greater in the 
glycolytic white versus the oxidative red portions of those muscles. 
 
Effects of SMTC on respiratory skeletal muscle, kidney and splanchnic organ blood flow and VC 
 Blood flow and VC were reduced in the diaphragm and intercostal muscles following 
SMTC compared to control (Table 3.3, p<0.05).  Blood flow and VC to the kidneys and all 
organs of the splanchnic region were not different between control and SMTC conditions (Table 
3.3, p>0.05 for all) 
 
Low-speed group 
Similar to both the high-speed group and our previous report (6), SMTC increased resting 
MAP (↑11±2 mmHg, p<0.05) and reduced HR (↓38±16 bpm) compared to control.  In marked 
contrast to the high-speed group, during treadmill running at 20 m/min SMTC had no effects on  
MAP, HR, or blood flow and VC to the total hindlimb musculature (Figure 3.2) or any individual 
muscle or muscle part compared to control (p>0.05  for all).  Similarly, diaphragm and 
intercostal muscle blood flow and VC were not different between conditions (p>0.05).  SMTC 
reduced blood flow and VC to the kidneys, adrenals, stomach, and small intestine (p<0.05 for 
all). As these data replicated closely those published previously (6), in the interests of brevity 
and clarity herein the reader is referred to that publication.  
 
Efficacy and selectivity of nNOS inhibition with SMTC 
SMTC followed by L-NAME administration produced a step-like increase in MAP above 
control values (Figure 3.5A, left panel).  Conversely, when the drug administration order was 
reversed, SMTC administered in the presence of prior L-NAME administration produced no 
further MAP increase (Figure 3.5A, right panel).  The magnitude (Δ MAP, Figure 5B, left panel) 
and recovery speed (time to 50% MAP recovery, Figure 5B, right panel) of the hypotensive 
response to ACh infusions were not different between control and SMTC conditions whereas 
they were blunted significantly following L-NAME. 
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 Discussion 
Consistent with our hypothesis, nNOS inhibition with SMTC reduced rat hindlimb 
skeletal muscle blood flow and VC during high-speed treadmill running (52.5±1.3 m/min) above 
critical speed.  Reductions in blood flow and VC were found in some muscles and muscle 
portions across the range of oxidative capacities and fiber-type compositions, however, the 
greatest relative reductions were found predominantly within glycolytic muscles composed 
primarily of type IIb+d/x fibers.  The SMTC-induced reductions in skeletal muscle blood flow 
and VC during high-speed running directly oppose the lack of effects of nNOS inhibition with 
SMTC on blood flow or VC in any individual muscle or muscle part during low-speed (20 
m/min) running.  The present data reveal important fiber-type and exercise intensity dependent 
peripheral vascular effects of nNOS-derived NO during whole-body locomotory exercise. 
 
Relationship with the literature 
 Low-intensity exercise recruits primarily motor units innervating oxidative slow- and 
fast-twitch muscle fibers whereas motor units innervating glycolytic fast-twitch muscle fibers are 
recruited additively as exercise intensity increases (13, 23).  For high-intensity exercise the 
critical speed (or power) represents an important metabolic rate where exercise performed above 
critical speed/power systematically drives 2OV
  toward its maximum value (2, 31).  In the rat, 
supra-critical speed treadmill running elicits marked preferential type IIb and d/x fast-twitch 
muscle fiber recruitment (5).  That nNOS inhibition reduced relative blood flow and VC during 
supra-critical speed running to the greatest extent in glycolytic fast-twitch muscles in the present 
investigation is a crucial extension of the previous findings that nNOS-derived NO attenuates 
sympathetic vasoconstriction in glycolytic but not oxidative muscles during electrically-induced 
rat muscle contractions (38-40).  Moreover, artificial simultaneous recruitment of all motor units 
may explain why nNOS inhibition reduced skeletal muscle blood flow and VC during 
electrically-induced contractions of the mixed muscle-fiber type rats spinotrapezius muscle (4).  
A fiber-type selective vascular effect of nNOS-derived NO is consistent with the identification of 
greater nNOS activity in predominantly type II, compared to type I, rat muscles (21) although 
human oxidative type I muscle may actually contain more nNOS than type II muscle (10).  The 
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mechanisms of nNOS-mediated vasomotor control within glycolytic type II muscle during high-
speed running likely involves attenuation of the exercise-induced augmented sympathetic 
vasoconstrictor signal (i.e., functional sympatholysis) mediated via α2-adrenergic receptors (38, 
39).  Although a more direct vasodilatory role for nNOS-derived NO has also been identified in 
rat fast-twitch muscle (14) acting presumably via alterations in intra-smooth muscle cell cyclic 
guanosine monophospate (cGMP) concentration.  
 In the present investigation the absolute magnitude of SMTC-induced reductions in BF 
and VC were similar between some oxidative and glycolytic muscles.  However, those 
reductions were not consistent or statistically significant in the majority of the oxidative muscles.  
A noted exception is the adductor longus which is only 5% type IIb+d/x muscle fibers according 
to the histochemical analysis of Delp and Duan (7).  Interestingly, using immunological methods, 
Eng and colleagues (9) reported that the adductor longus is comprised of ~97% type IIb+d/x 
fibers.  Thus, our present conclusion of a selective, but not exclusive, influence of nNOS 
inhibition within glycolytic fast-twitch muscles during high-speed running (as depicted, for 
example, in Figure 3.3) may actually be an underestimation.  Furthermore, emphasis is placed on 
the relative reductions in blood flow and VC following SMTC herein because this designates the 
magnitude of the nNOS-derived NO signal relative to other vasodilator candidates within the 
individual muscles.  Any pathological disruption in nNOS-mediated function (and resultant 
impairments in O2 delivery) would lower the microvascular PO2 in proportion to its relative 
vasomotor contribution.  Thus, dysfunctional nNOS signaling would reduce microvascular PO2 
to the greatest extent in glycolytic muscles.  This would presumably incur major negative 
consequences for capillary-myocyte O2 flux, metabolic control, and contractile performance 
within those fibers (37); especially considering that glycolytic muscles evidence lower 
microvascular PO2 values compared to oxidative muscles in the control condition (24).   
In addition to muscle metabolic and contractile characteristics as reported presently, it is 
likely that other factors, for example, muscle contraction intensity (38), metabolic rate, and/or 
muscle function also influence the presence and extent of nNOS-derived NO vasomotor control.  
In support of the latter, nNOS inhibition with SMTC reduced blood flow and VC within 
predominantly oxidative rat hindlimb muscles at rest where muscle function (i.e., postural 
recruitment) may dictate nNOS-mediated vascular control.  It is also noteworthy that blood flow 
and VC were reduced following SMTC in the intercostals and highly oxidative diaphragm 
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(although comprised of 50% type IIb+d/x muscle fibers) muscles during high-speed but not low-
speed running.  Admittedly, force generation by these respiratory muscles was not necessarily 
matched before and after SMTC (as it was for the hindlimb muscles, a key feature of the current 
experimental design).  Force generation/recruitment was, if anything, likely enhanced given the 
well-characterized inhibitory effects of nNOS-derived NO on skeletal muscle contractile 
function (21) and the lower arterial PCO2 which indicates a greater exercise-induced 
hyperventilation likely increasing respiratory muscle work.  Therefore, the lower blood flow and 
VC following nNOS inhibition within the diaphragm and intercostals may well reflect a 
particularly important vasodilatory role for nNOS-derived NO in those muscles. 
 In the present investigation nNOS inhibition with SMTC did not reduce blood flow or 
VC to the kidneys or any splanchnic organs during high-speed running.  This contrasts with the 
obligatory nNOS-derived NO renal vascular control reported by our laboratory (present data, 6) 
and others (18, 42).  However, high exercise intensities elicit marked sympathetically-induced 
vasoconstriction within non-muscular tissues and inactive muscle thereby promoting cardiac 
output redistribution towards active skeletal muscle.  This is evidenced by the lower kidney and 
splanchnic organ blood flows and VCs compared to that found in the rat at rest and during low-
speed treadmill running (6).  At high exercise intensities obligatory nNOS-derived NO kidney 
and splanchnic organ vascular control may be obviated in order to facilitate this blood flow 
redistribution. 
 nNOS has been identified within nerves, skeletal muscle, and key cardiovascular control 
centers in the brain (29, 36).  Importantly, an identical systemic SMTC dose as used herein does 
not impact lumbar or renal sympathetic nerve discharge (author’s unpublished observations).  
This supports that the effects of SMTC observed presently reflect peripheral nNOS-derived NO 
vascular control specifically. 
 
Efficacy and selectivity of nNOS inhibition with SMTC 
 The efficacy and selectivity of nNOS inhibition herein is supported by: 1) the lack of 
further MAP increase with SMTC in the presence of prior L-NAME administration (Figure 5A, 
right panel), 2) the previously reported 17-fold selectivity of SMTC for nNOS over eNOS in rat 
tissue in vivo (11), 3) a comprehensive SMTC dose-response analysis indicating marked 
selectivity of SMTC for nNOS over eNOS at low doses (i.e., <1.0 mg/kg; 42), and 4) the present 
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demonstration that 0.56 mg/kg of SMTC did not alter the hypotensive response to ACh whereas 
it was blunted significantly following non-selective NOS inhibition with L-NAME.  Importantly, 
higher SMTC doses also blunt the hypotensive response to ACh (22, 42) thus supporting the 
sensitivity of this assessment as an indicator of nNOS selectivity.  Analysis of the hypotensive 
response to ACh has been utilized extensively to assess the selectivity of SMTC for nNOS in 
conscious rats (6, 42) and humans (34, 35) although we acknowledge that systemic ACh infusion 
may not necessarily impact eNOS exclusively.  However, it is also compelling that non-selective 
NOS inhibition with L-NAME in the rat running at low (17) and high (26) speeds markedly 
reduces blood flow and VC with the greatest effects observed in highly oxidative muscles.  In 
direct contrast, 0.56 mg/kg of SMTC did not impact blood flow or VC whatsoever during low-
speed running and the greatest relative reductions during high-speed running were found 
primarily within glycolytic fast-twitch muscles.  Had the SMTC dose utilized herein been so 
high as to inhibit eNOS at least some effects would have been anticipated during low-speed 
running.  Therefore, we believe that SMTC as used presently did not impact eNOS-mediated 
function. 
 
Conclusions 
 In the present investigation, selective nNOS inhibition with SMTC reduced skeletal 
muscle blood flow and VC principally within highly glycolytic fast-twitch muscle during high-
speed treadmill running above critical speed.  These pronounced effects of nNOS inhibition 
during supra-critical speed exercise differ dramatically from the lack of effects observed at low 
running speeds (present data, 6).  This identifies, for the first time, that nNOS-derived NO is an 
integral controller of skeletal muscle blood flow and in a fiber-type and exercise intensity 
dependent manner during whole-body locomotory exercise that contrasts markedly from eNOS-
derived NO.  Specifically, eNOS (plus nNOS) blockade with L-NAME induces the greatest 
blood flow and VC decrements in the most highly oxidative fibers and, as such, is manifested at 
both low and high running speeds.  The present investigation has important implications for 
cardiovascular disorders associated with reduced NO bioavailability and blood flow impairments 
during exercise and diseases associated specifically with altered nNOS structure and/or function. 
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Table 3.1. Effects of nNOS inhibition on MAP and HR 
 
 Control SMTC 
Rest   
     MAP (mmHg) 125±4 137±5* 
     HR (bpm) 410±9 393±11* 
Exercise   
     MAP (mmHg) 130±4 139±4* 
     HR (bpm) 538±6
†
 555±11
†
 
  
Effects of nNOS inhibition with SMTC on MAP and HR at rest and during high-speed treadmill 
running (15% above critical speed, 52.5±1.3 m/min). Data are mean±SEM, *p<0.05 versus 
control.  
†
p<0.05 versus rest. 
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Table 3.2. Effects of nNOS inhibition on blood flow and VC 
 Blood flow  VC 
 Control SMTC  Control SMTC 
Ankle extensors      
   Soleus (21.3, 9%) 366±37 309±14  2.87±0.37 2.23±0.11* 
   Plantaris (21.8, 80%) 394±29 382±16  3.04±0.20 2.75±0.11 
   Gastrocnemius, red (36.2, 14%) 566±48 533±22  4.40±0.42 3.85±0.22* 
   Gastrocnemius, white (8.1, 100%) 141±24 99±12*  1.10±0.19 0.71±0.09* 
   Gastrocnemius, mixed (25.7, 91%) 284±25 255±6  2.21±0.22 1.84±0.09* 
   Tibialis posterior (18.3, 73%) 347±41 334±26  2.70±0.33 2.41±0.21 
   Flexor digitorum longus (10.6, 68%) 187±47 145±20  1.46±0.37 1.06±0.17 
   Flexor halicus longus (12.3, 71%) 183±18 153±9*  1.42±0.14 1.10±0.07* 
      
Ankle flexors      
   Tibialis anterior, red (39.3, 63%) 572±79 429±44*  4.50±0.76  3.12±0.40* 
   Tibialis anterior, white (18.4, 80%) 222±42 156±22*  1.75±0.40 1.14±0.19* 
   Extensor digitorum longus (21.6, 76%) 107±19 90±18  0.84±0.16 0.66±0.15* 
   Peroneals (20.3, 67%) 222±26 143±15*  1.73±0.21 1.05±0.13* 
      
Knee extensors      
   Vastus intermedius (33.2, 4%) 585±50 520±33  4.52±0.34 3.76±0.28* 
   Vastus medialis (20.2, 82%) 424±36 383±12  3.27±0.21 2.76±0.09* 
   Vastus lateralis, red (42.3, 35%) 482±99 476±72  3.61±0.67 3.39±0.50 
   Vastus lateralis, white (8.3, 100%) 188±24 144±19*  1.47±0.21 1.05±0.16* 
   Vastus lateralis, mixed (19.2, 89%) 336±29 325±13  2.60±0.22 2.35±0.14 
   Rectus femoris, red (25.6, 66%) 458±50 399±33  3.51±0.32 2.89±0.28* 
   Rectus femoris, white (15.1, 100%) 267±29 218±18*  2.06±0.20 1.58±0.15* 
      
Knee flexors      
   Biceps femoris, anterior (8.4, 100%)  127±26 95±19*  1.01±0.23 0.70±0.16* 
   Biceps femoris, posterior (14.0, 92%) 191±23 150±11*  1.50±0.21 1.09±0.11* 
   Semitendinosus (12.6, 83%) 88±15 55±7*  0.69±0.13 0.40±0.06* 
   Semimembranosus, red (20.6, 72%) 316±46 259±21  2.47±0.40 1.88±0.17* 
   Semimembranosus, white (10.2, 100%) 135±32 95±17*  1.06±0.27 0.69±0.13 
      
Thigh adductors      
   Adductor longus (18.9, 5%)1 378±70 269±44*  2.98±0.64 1.94±0.31* 
   Adductor magnus & brevis (18.5, 89%) 204±38 158±22*  1.60±0.33 1.14±0.16* 
   Gracilis (15.4, 77%) 89±25 53±9*  0.69±0.19 0.38±0.07* 
   Pectinius (20.2, 69%) 176±73 136±81  1.43±0.66  1.04±0.65* 
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(Table 3.2 continued) 
Effects of nNOS inhibition with SMTC on individual hindlimb muscle or muscle part blood flow 
(ml/min/100g) and vascular conductance (VC, ml/min/100g/mmHg) during high-speed treadmill 
running (15% above critical speed, 52.5±1.3 m/min).  Data are mean±SEM.  Numbers in 
parentheses represent the citrate synthase activity (μmol/min/g) and percent sum of type IIb+d/x 
muscle fibers, respectively, as reported previously by Delp and Duan (7).  
1
See text for 
comments regarding contrasting report of the adductor longus muscle fiber-type composition by 
Eng et al. (9).  *p<0.05 versus control. 
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Table 3.3. Effects of nNOS inhibition on blood flow and VC 
  Blood flow  VC 
  Control SMTC  Control SMTC 
Diaphragm (39.1, 50%)  355±55 267±27*  2.76±0.43 1.94±0.23* 
Intercostals (12.0, ~82%)  60±7 47±4*  0.47±0.06 0.34±0.03* 
       
Kidney  318±65 255±57  2.46±0.48 1.81±0.38 
Stomach  35±5 29±4  0.28±0.05 0.20±0.03 
Adrenals  227±51 158±28  1.77±0.40 1.13±0.19 
Spleen  19±5 24±6  0.15±0.04 0.17±0.04 
Pancreas  59±10 42±4  0.47±0.09 0.30±0.02 
Small intestine  164±32 141±16  1.29±0.27 1.00±0.10 
Large intestine  97±17 86±12  0.76±0.14 0.61±0.08 
Liver
2
  18±4  21±4  0.14±0.03 0.15±0.03 
 
Effects of nNOS inhibition with SMTC on respiratory skeletal muscle, kidney, and splanchnic 
organ blood flow (ml/min/100g) and vascular conductance (VC, ml/min/100g/mmHg) during 
high-speed treadmill running (15% above critical speed, 52.5±1.3 m/min).  Data are mean±SEM.  
Numbers in parentheses represent the citrate synthase activity (μmol/min/g) and percent sum of 
type IIb+d/x muscle fibers, respectively, as reported previously by Delp and Duan (7).  
2
Denotes 
arterial, not portal, blood flow and VC.  *p<0.05 versus control.   
58 
 
Figure 3.1. Estimation of critical speed for a representative rat 
 
Estimation of critical speed (represented by the horizontal dashed lines) via the hyperbolic and 
linear 1/time models for a representative rat. 
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Figure 3.2. Effects of nNOS inhibition on hindlimb skeletal muscle blood flow and VC 
 
Effects of nNOS inhibition with SMTC (0.56 mg/kg) on hindlimb skeletal muscle blood flow 
and vascular conductance (VC) during treadmill running at 20 m/min (from present low-speed 
group) and 15% above critical speed (CS+15%, 52.5±1.3 m/min). *p<0.05 versus control. 
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Figure 3.3. Relative changes in blood flow and VC following nNOS inhibition 
 
Relative changes in blood flow (Δ blood flow) and VC (Δ VC) following nNOS inhibition with 
SMTC (0.56 mg/kg) in the highly oxidative and highly glycolytic muscles and muscle parts 
during high-speed treadmill running.  Oxidative muscles (n=5, adductor longus, red portion of 
the vastus lateralis, vastus intermedius, soleus, and red portion of the gastrocnemius) are 
comprised of  ≤35% type IIb+d/x fibers and have 3-fold higher citrate synthase activity versus 
glycolytic muscles (7).  Glycolytic muscles (n=5, anterior portion of the biceps femoris, white 
portions of the semimembranosus, rectus femoris, gastrocnemius, and vastus lateralis) are 
comprised of 100% type IIb+d/x fibers (7).  *p<0.05 versus oxidative,
 †
p<0.05 versus zero. 
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Figure 3.4. Relative changes in blood flow and VC following nNOS inhibition 
 
Relative changes in blood flow (Δ blood flow) and vascular conductance (Δ VC) following 
nNOS inhibition with SMTC (0.56 mg/kg) for oxidative red and glycolytic white portions of 
representative individual muscles during high-speed treadmill running.  Oxidative red (dashed 
lines and filled circles): 47±14% type IIb+d/x muscle fibers and 3-fold higher citrate synthase 
activity versus glycolytic white portions (7).  Glycolytic white (solid lines and open circles): all 
100% type IIb+d/x muscle fibers (7).  VL, vastus lateralis; Semim, semimembranosus; RF, 
rectus femoris; Gastroc, gastrocnemius.  SEM bars are omitted for clarity (range across all 
muscles 4-12%).  *p<0.05 versus control. 
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Figure 3.5. MAP data demonstrating the efficacy and selectivity of nNOS inhibition  
 
A) The step-like MAP increase when SMTC preceded L-NAME (left panel, high-speed group, 
n=6) and the lack of any further MAP increase when SMTC followed L-NAME (right panel, 
n=5) confirm that SMTC mediated its effects via nNOS inhibition.  B) The lack of effects of 
SMTC on the magnitude (left panel) and recovery speed (right panel) of the hypotensive 
response to ACh is consistent with intact eNOS-mediated function (high-speed group, n=6).  
*p<0.05 versus control, 
†
p<0.05 versus SMTC. 
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Chapter 4 - Role of neuronal nitric oxide synthase in modulating 
skeletal muscle microvascular and contractile function 
68 
 
 
 Summary 
The present study tested the hypothesis that selective neuronal nitric oxide synthase 
(nNOS) inhibition would lower the dynamic microvascular O2 delivery/utilization ( )2OV
 balance 
(which sets the microvascular O2 partial pressure; PO2mv) in rat skeletal muscle at rest and 
during contractions.  Anesthetized male Sprague-Dawley rats had their spinotrapezius muscles 
exposed for blood flow (radiolabelled microspheres), 2OV

 (direct Fick calculation), PO2mv 
(phosphorescence quenching), or exteriorized for force production measurement during 
electrically-induced contractions (1 Hz, 6-8 V, 180 s) pre- and post-nNOS inhibition with 2.1 
μmol/kg of S-methyl-L-thiocitrulline (SMTC).  At rest, spinotrapezius blood flow was not 
different whereas SMTC reduced 2OV
  (↓27%) resulting in an elevated pre-contracting baseline 
PO2mv (control: 31.2±1.6, SMTC: 37.1±2.0 mmHg, p<0.05).  Following contractions onset 
SMTC speeded the time to reach 63% of the overall PO2mv kinetics response (control: 22.5±1.6, 
SMTC: 16.9±1.4 s, p<0.05).  During the contracting steady-state, SMTC reduced spinotrapezius 
blood flow (↓17%) and 2OV
  (↓17%) such that PO2mv was not different (control: 22.8±1.6, 
SMTC: 22.7±2.1 mmHg, p>0.05) which occurred despite an elevated (↑~8%) muscle force 
production.  These data demonstrate important physiological roles for nNOS-derived NO during 
contractions in healthy rat skeletal muscle and implicate maladaptations in nNOS function in 
pathological conditions associated with reduced NO bioavailability. 
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 Introduction 
Nitric oxide (NO) derived from constitutively expressed neuronal (type I) and endothelial 
(type III) NO synthase (NOS) has been identified as an important signaling molecule with a vast 
array of physiological functions.  Given that global endothelial dysfunction represents an 
important biomarker and predictor of functional capacity and quality of life (2), the potential role 
of endothelial NOS (eNOS) rather than neuronal NOS (nNOS) in modulating peripheral vascular 
tone has been a principal focus of experimental enquiry. 
More recently, however, novel investigations have identified specific roles for nNOS-
derived NO in the regulation of vascular function and O2 delivery (12, 23, 32, 48, 49, 51).  For 
example, mice lacking nNOS evince impaired modulation of sympathetic vasoconstrictor 
influence (i.e., functional sympatholysis; 15, 51, 52) and augmented smooth muscle contractile 
protein phosphorylation (21) which culminates in reduced active skeletal muscle blood flow 
during treadmill exercise (35).  Furthermore, in healthy subjects pharmacological selective 
nNOS blockade reduced resting blood flow in humans (48, 49) and animals (12) but, contrary to 
data from mice lacking nNOS, did not alter active skeletal muscle blood flow during treadmill 
running exercise in the rat hindlimb (12).  Thus, the precise role of nNOS-derived NO in 
regulating O2 delivery to active skeletal muscle remains controversial.  One important 
consideration in this regard is that nNOS-derived NO may modulate a variety of intramyocyte 
processes.  For example, within skeletal muscle it has been shown that NO may exert inhibitory 
influences on both contractile function (3, 45) and mitochondrial respiration (9).  In light of these 
diverse NO-mediated effects, it is surprising that no study has yet investigated the precise role(s) 
of nNOS-derived NO in regulating O2 delivery in specific relation to local O2 demand.  Within 
the skeletal muscle microvasculature the local O2 delivery-to-O2 utilization )( 2OV

 ratio sets the 
microvascular partial pressure of O2, PO2mv and constitutes the sole pressure-head for capillary-
myocyte O2 flux according to Fick’s law of diffusion.  An enhanced understanding of the role of 
nNOS-derived NO in controlling the dynamic and steady-state PO2mv response during muscle 
contractions would be particularly important given the crucial role of O2 availability in 
determining muscle performance.  This information would be beneficial for the many chronic 
clinical conditions are associated with derangements in nNOS structure and/or function (53). 
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Therefore, the purpose of the present investigation was to explore the effects of nNOS 
inhibition via the selective nNOS inhibitor S-methyl-L-thiocitrulline (SMTC, which possesses a 
17-fold selectivity for nNOS versus eNOS; 19) administered prior to contractions of an in situ 
skeletal muscle on the regulation of dynamic skeletal muscle PO2mv response during 
contractions.  Based on the evidence summarized above, we tested the hypothesis that selective 
nNOS inhibition via SMTC would: 1) reduce resting but not contracting muscle blood flow, 2) 
increase resting and contracting muscle ,2OV
  3) lower the muscle O2 delivery/ 2OV  ratio (i.e., 
PO2mv) at rest and during the rest-contractions transition, and 4) increase muscle force 
production. 
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 Methods 
Animals  
26 total young (4-5 months, body mass 459±14 g) male Sprague-Dawley rats (Charles 
River Laboratories, Wilmington, MA, USA) were housed 2 per cage in accredited facilities and 
maintained on a 12:12 hour light-dark cycle with food and water provided ad libitum.  All 
experimental protocols described presently were approved by the Institutional Animal Care and 
Use Committee of Kansas State University and conducted in accordance with federally mandated 
guidelines. 
 
Surgical preparation 
All rats were anesthetized initially with a 5% isoflurane-O2 mixture and maintained on 2-
3% isoflurane-O2.  The carotid and caudal (tail) arteries were cannulated (Polyethelene-50, Intra-
Medic Tubing, Clay Adams Brand, Becton, Dickinson and Company, Sparks, MD, USA) for 
continuous monitoring of heart rate (HR) and mean arterial pressure (MAP), infusion of the 
phosphorescent probe, and/or blood flow measurement via radiolabelled microsphere injection 
(see below).  Following placement of the catheters, the animals were gradually transitioned to 
pentobarbital sodium (administered i.a. to effect).  The level of anesthesia was monitored 
continuously throughout the experiment via toe-pinch and blink reflexes and was supplemented 
as necessary.  Anesthetized rats were placed on a heating pad to maintain core temperature, 
measured via rectal probe, at ~37-38 C.   
For PO2mv measurement, overlying skin and adipose tissue was removed surgically from 
the right side of the dorsal, mid-caudal region of each rat exposing the right spinotrapezius 
muscle in a manner preserving the muscles vascular and neural supply.  For example, our 
laboratory has demonstrated previously similar blood flow responses may be obtained among 
intact (non-exposed), exposed, and exteriorized spinotrapezius muscles (4) indicating that 
potential inflammatory responses as a result of surgical preparation do not confound data 
interpretation at least in regards to the principal measurements made herein.  Exposed muscle 
was moistened constantly throughout the surgery and experimental protocol via superfusion of 
Krebs-Henseleit bicarbonate-buffered solution (equilibrated with 5% CO2, 95% N2, pH 7.4, 
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warmed to 37 C) and surrounding tissue was covered with Saran™ wrap (Dow Brands, 
Indianapolis, IN, USA).  Silver wire electrodes were sutured to the rostral (cathode) and caudal 
(anode) region of the muscle to elicit electrically-induced muscle contractions.  The 
spinotrapezius muscle is ideal for investigations of microvascular and metabolic function given 
that it is optimally located for surgical exposure/exteriorization and possesses a mosaic of 
muscle-fiber types and a citrate synthase activity similar to the human quadriceps (13, c.f., 36). 
 
Measurement of PO2mv 
In 10 rats, the phosphorescent probe palladium meso-tetra (4-carboxyphenyl) porphyrin 
dendrimer (R2: 15-20 mg/kg dissolved in saline) was infused via the carotid artery catheter.  
After a ~10-15 minute stabilization, the carotid artery catheter was connected to a pressure 
transducer for continuous monitoring of HR and MAP, PO2mv measurement (see below) was 
initiated.  Confirmation of a valid preparation with intact arteriolar tone required a stable PO2mv 
for a minimum of 30 s and within ±10 mmHg of the value established for this measurement in 
the young healthy rat (i.e., 31.4 mmHg; 8).  Subsequently, 1.2 ml of heparinized saline was 
infused at a rate of 0.2 ml/min into the caudal artery catheter to serve as a control infusion.  
Following the infusion the caudal artery catheter was connected to a 1 ml plastic syringe and 
placed in a withdrawl pump (model 907, Harvard Apparatus, Cambridge, MA, USA).  
Subsequently, 1 Hz (~6-8 V, 2 ms pulse duration) twitch contractions were elicited via a 
stimulator (model S88, Grass Instrument Co., Quincy, MA, USA).  At 180 seconds of 
contractions blood withdrawal from the tail catheter was initiated at a rate of 0.25 ml/min, the 
carotid catheter was disconnected from the pressure transducer, and ~0.5-0.6x10
6
 15 μm 
radiolabelled microspheres (
46
Sc or 
85
Sr in random order, Perkin Elmer Life and Analytical 
Sciences, Boston, MA, USA) were injected into the aortic arch for determination of blood flow 
(see below for details), and contractions were then terminated.  Following a minimum 20 minute 
recovery period, 0.56 mg/kg (2.1 μmol/kg) of SMTC was dissolved in 1.2 ml of heparinized 
saline and infused as described above.  Following the infusion and once it was observed that 
PO2mv was stable for at least 30 seconds, contraction and microsphere injection protocols were 
performed exactly as described for control.  Blood samples were taken after each contraction 
protocol to determine arterial PO2, O2 saturation, pH, and blood [lactate].  In a separate group of 
animals (n=5) acetylcholine (ACh) infusions (10 μg/kg in 0.2 ml of saline) were performed 
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under control and SMTC conditions as well as following non-selective NOS inhibition with 10 
mg/kg of N
G
-nitro-L-arginine-methyl-ester (L-NAME) administered into the caudal artery.  The 
hypotensive responses to these infusions were recorded in order to confirm the efficacy of 
selective nNOS inhibition in the presence of SMTC in anesthetized rats.  At the end of each 
experiment, rats were euthanized via an intra-arterial pentobarbital overdose (~50 mg/kg). 
 
Determination of muscle blood flow and calculation of 2OV
  
Upon completion of each experiment, the right and left spinotrapezius muscles and 
kidneys were carefully dissected, removed and weighed.  The radioactivity of the individual 
tissues and reference blood samples taken from the tail artery catheter during microsphere 
injections were determined via a gamma scintillation counter (Auto Gamma Spectrometer, Cobra 
model 5003, Hewlett-Packard, Downers Grove, IL, USA) and individual tissue blood flows were 
determined by the reference sample method (26) and expressed in milliliters per minute per 100 
grams of tissue.  In each condition (control and SMTC) the stimulated right, and non-stimulated 
left spinotrapezius muscles represented the contracting and resting blood flow measurements, 
respectively.  Vascular conductance (VC) was determined as the ratio of blood flow to MAP 
using the MAP measured immediately prior to microsphere injection.  All rats exhibited <15% 
difference in blood flow between the right and left kidneys which indicated an adequate mixing 
of microspheres during the blood flow determinations. 
 2OV
  was calculated from blood flow and PO2mv as described previously (6).  Arterial O2 
concentration (CaO2) was calculated directly from arterial blood samples and venous muscle 
effluent blood O2 concentration (CvO2) was estimated from either the baseline (rest) or the 
contracting steady-state (contractions) PO2mv using the rat dissociation curve (Hill’s coefficient 
of 2.6), the measured hemoglobin (Hb) concentration, a P50 of 38 mmHg, and an O2 carrying 
capacity of 1.34 ml O2/g Hb (1).  The measures of the resting and contracting spinotrapezius 
blood flows were then used to determine 2OV
  via the direct Fick calculation (i.e., 2OV = blood 
flow x (CaO2 – CvO2)). 
 
Measurement of PO2mv and curve-fitting 
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The principles of the phosphorescence quenching technique have been discussed 
previously (8).  The Stern-Volmer relationship allows the calculation of PO2mv through the 
direct measurement of a phosphorescence lifetime via the following equation (46): 
 
PO2mv = [(τ/ τ)-1]/(kQ x τ)   
 
where kQ is the quenching constant (expressed in mmHg
-1/s) and τ and τ are the 
phosphorescence lifetimes in the absence of O2 and the ambient O2 concentration, respectively.  
For R2, kQ is 409 mmHg
-1/s and τ is 601 µs (37) and these characteristics do not change over 
the physiological range of pH and temperature in the rat in vivo and, therefore, the 
phosphorescence lifetime is determined directly by the O2 pressure (37, 46).   
The R2 phosphorescent probe binds to albumin, and consequently, is uniformly 
distributed throughout the plasma.  In rat skeletal muscle albumin has a reflection coefficient of 
0.98-0.99 (43, 44) thus limiting its filtration into surrounding tissue.  A previous study from our 
laboratory investigated systematically the compartmentalization of R2 and confirmed that it 
remains within the microvasculature of exposed muscle over the duration considered in the 
present experiments, thereby ensuring a valid measurement of PO2mv (39).  The PO2mv was 
determined with a PMOD 5000 Frequency Domain Phosphorometer (Oxygen Enterprises, 
Philadelphia, PA, USA).  The common end of the light guide was placed ~2-4 mm superficial to 
the dorsal surface of the exposed right spinotrapezius muscle.  The randomly selected muscle 
field was comprised principally of capillary blood and PO2mv was measured continuously and 
recorded at 2 second intervals throughout the duration of the contraction periods. 
For the measured PO2mv responses, curve-fitting was performed with commercially 
available software (SigmaPlot 11.2, Systat Software, San Jose, CA, USA) and the data were fit 
with either a one- or two-component model as described below: 
 
One component: PO2mv(t) = PO2mv(BL) – ΔPO2mv(1 – e
-(t - TD)/ τ
) 
Two component: PO2mv (t) = PO2mv (BL) – Δ1PO2mv (1 – e
-(t – TD1)/ τ1) + Δ2PO2mv (1 – e
-(t – TD2)/ τ2) 
 
where PO2mv(t) represents the PO2mv at any given time t, PO2mv (BL) corresponds to the pre-
contracting resting PO2mv, Δ1 and Δ2 are the amplitudes for the first and second component, 
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respectively, TD1 and TD2 are the time delays for each component, and τ1 and τ2 are the time 
constants (i.e., time to 63% of the final response value) for each component.  Goodness of fit was 
determined using the following criteria: 1) the coefficient of determination (r
2
), 2) sum of the 
squared residuals, and 3) visual inspection and analysis of the model fits to the data and the 
residuals.  The mean response time (MRT, time taken to reach 63% of the overall dynamic 
response) of the kinetics response was calculated for the first component in order to provide an 
index of the overall principal kinetics response according to the following equation (25, 38): 
 
MRT = TD1 + τ1 
 
where TD and τ are as described above.  The time taken to reach 63% of the final response 
PO2mv was determined independent of modeling procedures (T63) to ensure appropriateness of 
the model fits.  Specifically, the raw PO2mv data was interpolated and the time coinciding with 
63% of the initial amplitude was determined.  The delta of the initial PO2mv fall following 
contractions onset was normalized to τ (Δ1PO2mv/τ1) to provide an index of the relative rate of 
fall. 
 
Measurement of muscle force production 
 Due to differences in the surgical preparation required between measurements of muscle 
force production and PO2mv, an additional group of rats (n=5) was utilized to determine the 
effects of SMTC on muscle contractile function.  In these animals, the caudal end of the exposed 
spinotrapezius muscle was exteriorized and sutured to a thin, wire horseshoe manifold attached 
to a swivel apparatus and a non-distensible light-weight (0.4 g) cable which linked the muscle to 
a force transducer (model FTO3, Grass Instrument Co., Quincy, MA, USA).  The pre-load 
tension of the muscle was set at ~4-5 g which elicited the muscle’s optimum length for twitch 
force production.  Muscle force production was measured throughout control and SMTC 
contraction bouts which were identical to the contraction protocols described for the 
measurement of PO2mv. 
 
Control experiments 
76 
 
 The reproducibility of spinotrapezius muscle measurements has been addressed 
previously (10, 24) and was reconfirmed in the present study via time control experiments (n=6).  
The average coefficient of variation for PO2mv kinetics parameters and muscle force production 
was 12±4% with no ordering effects for any parameter (p>0.05 versus zero for all).  These data 
provide confidence that the significant effects detected herein were the direct result of SMTC 
administration. 
  
Statistical analysis 
Data are presented as mean±SEM.  All comparisons between or among control, SMTC, 
and L-NAME conditions were made using paired Students t-tests or repeated measures 
ANOVAs (Student-Newman-Keuls post-hoc where appropriate). When a directional hypothesis 
was tested a one-tail test was performed.  The significance level was set at p<0.05. 
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 Results 
Blood sampling, hemodynamic variables and ACh injections 
 There were no differences in arterial blood PO2 (control: 99.6±1.4, SMTC: 99.4±1.5 
mmHg), O2 saturation (control: 91.4±0.7, SMTC: 91.4±1.4%), or pH (control: 7.37±0.01, 
SMTC: 7.38±0.01) between conditions (p>0.05 for all).  Blood [lactate] was significantly 
different between control (0.99±0.08 mmol/L) and SMTC (1.12±0.08 mmol/L, p<0.05). 
HR and MAP did not change during the control saline infusion; however, MAP increased 
and HR decreased during the infusion of SMTC.  The effects of SMTC on MAP and HR at the 
end of infusion, at rest immediately prior to contractions onset, and during the contracting 
steady-state are displayed in Table 1. 
The time to 50% recovery of the hypotensive response to ACh injections was not 
different (p>0.05) between control and SMTC conditions (Figure 4.1).  Conversely, the recovery 
was speeded significantly compared to control and SMTC (p<0.05 for both) following L-NAME 
administration which is consistent with a lack of effect of SMTC on eNOS. 
 
PO2mv 
Average PO2mv during control and SMTC infusions are displayed in Figure 4.2.  PO2mv 
was not different between control and SMTC at the start or during the first 5 min of infusion 
(p>0.05 for all time points) but was significantly elevated by the end of infusion (6
th
 min) 
(35.5±2.1 mmHg) versus control (30.7±1.3 mmHg, p<0.05).  Average absolute and normalized 
PO2mv profiles during contractions are depicted in Figure 4.3 with average kinetics parameters 
displayed in Table 2.  The principal effects of SMTC were to increase the resting baseline 
PO2mv and reduce the time delay of the PO2mv fall which resulted in a speeding of the principal 
kinetics response (i.e., reduced MRT and T63 and increased Δ1PO2mv/τ1, p<0.05 between control 
and SMTC for all).  Within control and SMTC conditions there were no differences (p>0.05) 
between MRT and T63 which indicates that modeling procedures did not bias the kinetics 
analyses.  SMTC increased (p<0.05) the amplitude of the PO2mv fall during contractions such 
that steady-state PO2mv was not different (p>0.05) from control.  For both control and SMTC 
conditions the post-contractions PO2mv recovered to values that were not different (p>0.05 for 
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both) from their respective pre-contracting values which is consistent with a valid and stable 
preparation. 
 
Blood flow and 2OV
  
Resting and contracting spinotrapezius muscle blood flow and VC are displayed in Figure 
4.4.  Blood flow at rest was not different (p>0.05) whereas VC was significantly lower (p<0.05) 
following SMTC compared to control.  During contractions SMTC reduced significantly (p<0.05 
for both) spinotrapezius muscle blood flow and VC.  Delta blood flow and VC between rest and 
contractions were reduced (p<0.05 for both) after SMTC versus control.  Resting and contracting 
spinotrapezius muscle 2OV
  are displayed in Figure 4.5.  SMTC reduced spinotrapezius muscle 
2OV
  at rest and during contractions as well as the delta 2OV between rest and contractions 
(p<0.05 for all). 
 
Muscle force production 
 Average spinotrapezius muscle force-time integrals are displayed in Figure 4.6.  
SMTC increased significantly (p<0.05) the force-time integral by ~8% in the absence of altered 
baseline tension.  The average steady-state (180 second) force production-to- 2OV
 ratio was 
increased by ~31% following SMTC (control: 0.21±0.02, SMTC: 0.27 ± 0.03 g/μl/min, p<0.05). 
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 Discussion 
The present study has identified novel roles for nNOS-derived NO in healthy resting and 
contracting rat skeletal muscle.  Specifically, when compared to control, systemic selective 
nNOS inhibition via SMTC reduced resting spinotrapezius muscle 2OV

 resulting in an elevated 
resting baseline PO2mv.  During the contracting steady-state spinotrapezius blood flow and 2OV

 
were reduced in similar proportion such that PO2mv was not different between control and 
SMTC.  Moreover, blood flow and 2OV

 were reduced during contractions in the presence of an 
elevated muscle force production thereby increasing the economy (force/ )2OV

 of contractions.  
The present data unveil that, via marked effects on both metabolic and microvascular control, 
nNOS-derived NO has an integral role in setting the PO2mv during electrically-induced skeletal 
muscle contractions.  These data are consistent with observations that impaired nNOS-mediated 
structure and/or function is associated with alterations in the regulation of O2 delivery, 2OV
  and 
contractile function and have important implications for the litany of chronic clinical populations 
where the pathology is associated with reduced NO bioavailability. 
 
Comparison with the literature 
Despite the absence of effects on blood flow per se, in the present investigation nNOS 
inhibition with SMTC reduced resting spinotrapezius muscle VC which is generally consistent 
with observations that nNOS-derived NO regulates resting vascular tone in the human forearm 
(49), coronary arteries (48), and rat hindlimb muscle (12).  However, it is also worth considering 
that the lack of increase in blood flow in the face of increased muscle perfusion pressure may 
represent simply an autoregulatory mechanism that maintains O2 delivery.  Upon the initiation of 
contractions the time delay, and therefore MRT, of the PO2mv fall was reduced indicating that 
nNOS-derived NO mediates, in part, the rapid dynamic O2 delivery adjustment and/or limits the 
rate of 2OV

 increase upon contractions onset (17, 27, 28).  Importantly, the faster rate of PO2mv 
fall observed presently with nNOS inhibition resembles faster on-transient PO2mv responses 
reported in aged (7, 25) and chronic heart failure (14) rats; conditions which are associated with 
reduced NO bioavailability.  During the contracting steady-state SMTC reduced blood flow and 
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VC; effects which were not evident when SMTC was administered prior to conscious whole-
body treadmill exercise when speed and grade were independent variables (12).  It is possible the 
effects of anesthesia and/or the use of an isolated electrically-induced contractions protocol of a 
small muscle mass blunted redundant O2 delivery regulatory mechanisms that were present 
during conscious exercise.  More importantly, it is noteworthy that blood flow was reduced in 
direct proportion (i.e., both reduced by 17%) such that steady-state PO2mv was similar between 
conditions.  This may be interpreted to suggest that the effects on blood flow were secondary to 
alterations in metabolic rate and do not indicate specific vascular effects per se during 
contractions.  Therefore, the present data qualify and extend our previous findings in conscious 
rats running on a treadmill by unveiling a role for nNOS-derived NO in the regulation of active 
skeletal muscle vascular tone in healthy subjects when force production is allowed to change 
during electrically-induced muscle contractions. 
It may also be argued that the reduced blood flow during contractions simply reflects the 
increased vascular tone at rest limiting the contractions-induced vasodilation.  Intriguingly, it has 
been demonstrated that, in highly oxidative muscles, blood flow during treadmill running is 
better preserved when L-NAME is infused during rather than prior to exercise (11).  Whereas 
this was not the case for less oxidative muscle fibers in that instance (a category encompassing 
the spinotrapezius muscle) it should not be discounted that infusion of SMTC during 
contractions may potentially evoke a different response than observed herein. 
In contrast to our hypothesis, SMTC reduced resting and contracting spinotrapezius 
muscle 2OV

 which contrasts with the reported potential for NO to inhibit cytochrome c oxidase 
in the mitochondrial respiratory chain (9) and observations that non-selective NOS inhibition 
with L-NAME does not alter resting or contracting steady-state 2OV

 in dogs (22, 31) and 
humans (17, 27).  However, others have reported that L-NAME may attenuate the delta 2OV

 
between rest and contractions (22) and steady-state 2OV

 (30) during isolated contractions of the 
canine hindlimb.  Moreover, isolated contracting rat hindlimb 2OV

 was reduced following L-
NAME (5, 34) even at matched convective O2 delivery (34).  Our findings extend the 
observations in rat muscle by identifying that at least a portion of this influence is directly 
attributable to nNOS-derived NO.  Presently, SMTC reduced spinotrapezius 2OV

 at rest despite 
maintenance of blood flow and, therefore, O2 delivery, suggesting a stimulatory influence of 
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NOS-derived NO on mitochondrial function directly.  During contractions SMTC reduced 2OV

 
in direct proportion to blood flow such that PO2mv was unchanged.  This later observation makes 
interpretations concerning the influence of nNOS-derived NO on mitochondrial function per se 
during contractions challenging.  However, given that metabolic demand during contractions is 
influenced directly by the rate of ATP hydrolysis at the myofibrillar contractile elements, it is 
important to note that SMTC increased the contracting spinotrapezius muscle force-time integral 
identifying a contractile-inhibitory influence for nNOS-derived NO likely via alterations of 
sarcoplasmic reticulum calcium release (41), myofibrillar calcium sensitivity (3), and/or direct 
myofibrillar protein redox modification (20).  Accordingly, we speculate that the economy of 
contractions (average steady-state force production-to- 2OV

 ratio) was therefore increased 
through the combination of attenuation of inhibitory effects on muscle force production and 
stimulatory effects on 2OV

 in the present model.  These findings are consistent with observations 
that non-selective NOS inhibition reduces the O2 cost of tension development in the contracting 
rat (5, 34) and dog (30) hindlimb and implicates specifically nNOS-derived NO as a principal 
mediator. 
  
Efficacy of selective nNOS inhibition 
Despite the obvious scientific utility of genetically-altered nNOS knockout models, we 
chose to utilize acute selective nNOS inhibition to examine the role of nNOS-mediated function 
in healthy rats where there is no opportunity for chronic compensation of nNOS absence.  Thus, 
the efficacy of the selected SMTC dose (0.56 mg/kg or 2.1 μmol/kg) to inhibit nNOS without 
affecting eNOS-mediated function is crucial.  Several points support that this was successfully 
accomplished: 1) SMTC did not alter the hypotensive response to ACh injections whereas it was 
blunted (i.e., faster time to 50% recovery) after L-NAME (a non-selective inhibitor of nNOS and 
eNOS) which is consistent with previous reports from our laboratory in conscious rats (12).  2) 
The dose used presently is similar to other studies reporting selective nNOS inhibition with 
SMTC in rats in vivo (i.e., 0.5 mg/kg; 33, 0.3 mg/kg; 54).  3) The modest SMTC-induced MAP 
increases observed presently are substantially lower than those observed when L-NAME is 
administered following SMTC in these same rats where values may reach >150 mmHg (authors’ 
unpublished observations).  While we are confident that the present data reflect selective nNOS 
inhibition (i.e., eNOS inhibition was absent), it must also be considered that it is presently 
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impossible to determine if nNOS was fully inhibited.  Thus the present results may actually 
represent an underestimation of the full contribution of nNOS in modulating microvascular 
function. 
 
Experimental considerations 
 Stimulation paradigm:  During voluntary muscle contractions the magnitude of the 
hyperemia reflects the competition between enhanced neural vasoconstrictor tone (50, which 
may be offset by sympatholysis in active muscle; 42) and contractions-mediated vasodilation as 
well as mechanical factors relating to muscle pumping action.  The stimulation paradigm used 
herein was selected based upon its ability to: 1. Provide reproducible contraction bouts without 
fatigue. 2. Induce hyperemic response kinetics at the capillary level (29) that match those 
observed across muscles performing voluntary exercise (47). 3. Reproduce the proportional 
matching of blood flow and O2 delivery to 2OV

 as that present in animal and human muscles 
during voluntary exercise (16, 40).  The 2 ms pulse duration employed herein is expected to 
activate sympathetic perivascular nerves concomitant with inducing muscle fiber contraction, 
and, as such may help re-create the vasoconstriction/vasodilation competition found in vivo.  
That conditions 2 and 3 above are satisfied may reflect either a fortuitous/coincidental outcome 
or, more likely, that essential control features of the in vivo response are preserved despite the 
electrical stimulation necessary to evoke muscle contractions. 
Systemic versus local SMTC application:  The mandate to demonstrate selectivity of 
nNOS blockade (as opposed to eNOS) precluded local application (i.e., superfusion) of SMTC.  
Specifically, for any superfused preparation the rapid ACh infusion test, utilized herein to 
provide confidence that eNOS had not been blocked, is not valid.  Thus, whereas it must be 
acknowledged that the protocol used presently does not provide a rigorous discrimination 
between systemic versus local effects in all respects: there was clear evidence of nNOS 
selectivity (Figure 4.1). Insofar as contractile force and the ability to match O2 delivery with 2OV
  
are regulated by local events there can be confidence that SMTC-induced nNOS blockade within 
the muscle is responsible for the effects observed (i.e., increased tension and altered PO2mv at 
rest).  However, in the contracting muscle where both blood flow and 2OV

 were decreased, such 
that PO2mv was unaltered, more proximal (central) effects of SMTC on blood pressure 
regulation and possibly the neural regulation of vascular conductance including sympatholysis 
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cannot be discounted.   Given this situation it is intriguing that, although O2 delivery and 2OV
  
were both altered, their proportionality (as evidenced by the constancy of PO2mv) during 
contractions (but not at rest) was unperturbed. 
 
Conclusions 
The present investigation has identified that nNOS-derived NO sets the O2 
delivery/utilization balance (i.e., PO2mv) during contractions under the specific experimental 
conditions used presently via mirrored effects on metabolic )( 2OV

 and vascular (blood flow and 
VC) control.  Specifically, during electrically-induced twitch contractions when force output is 
allowed to change, nNOS inhibition reduced blood flow in proportion to 2OV
  such that the 
steady-state PO2mv was unaltered compared to the control condition.  These effects may be 
masked during conscious whole-body treadmill exercise when force output or work is a set 
independent variable (12).  In the present investigation force output was increased which, in 
conjunction with the SMTC-induced 2OV

 reduction, increased the economy of muscle 
contractions.  The present novel findings in healthy skeletal muscle further identify nNOS as a 
potential target for physiological and possibly pathological modulation of systemic 
hemodynamics as well as muscle metabolic and microvascular function.  These data carry 
important implications suggesting that future therapeutic interventions targeting nNOS may be 
successful in alleviating dysfunction in populations where the pathology is associated with 
reduced NO bioavailability. 
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Table 4.1. Effects of nNOS inhibition on HR and MAP 
 Control SMTC 
End-infusion   
     HR (bpm) 345±9 330±7* 
     MAP (mmHg) 113±6 130±7* 
Rest (pre-contractions)   
     HR (bpm) 339±11 319±7* 
     MAP (mmHg) 111±6 135±6* 
Contractions (steady-state)   
     HR (bpm) 340±11 323±9* 
     MAP (mmHg) 112±6 134±6* 
 
HR and MAP at rest prior to and during the steady-state of electrically-induced muscle 
contractions before (control) and after selective nNOS inhibition with SMTC.  Values are 
mean±SEM, *p<0.05 versus control.  Within each condition there were no differences among 
end-infusion, rest, or contractions HR and MAP. 
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Table 4.2. Effects of nNOS inhibition on contracting skeletal muscle PO2mv parameters 
 Control SMTC 
PO2mv(BL), mmHg 31.2±1.6 37.1±2.0* 
Δ1PO2mv, mmHg 10.2±0.4 14.7±1.4* 
Δ2PO2mv, mmHg 1.9±0.6 - 
ΔtotalPO2mv, mmHg 8.4±0.4 14.4±1.5* 
PO2mv(steady-state), mmHg 22.8±1.6 22.7±2.1 
TD1, s 8.2±0.8 5.1±0.6* 
TD2, s 27.8±4.4 - 
τ1, s 14.3±1.4 11.7±1.5 
τ2, s 29.7±1.4 - 
MRT, s 22.5±1.6 16.9±1.4* 
T63, s 21.1±1.8 17.3±1.6* 
Δ1PO2mv/τ1, mmHg/s 0.8±0.1 1.6±0.3* 
 
Microvascular partial pressure of O2 (PO2mv) kinetics parameters during contractions before 
(control) and after selective nNOS inhibition with SMTC.  Values are mean±SEM.  PO2mv(BL), 
pre-contracting PO2mv; Δ1PO2mv, amplitude of the first component; Δ2PO2mv, amplitude of the 
second component; ΔtotalPO2mv; overall amplitude regardless of one- or two-component model 
fit; PO2mv(steady-state), contracting steady-state PO2mv; TD1, time delay for the first component; 
TD2, time delay for the second component; τ1, time constant for the first component; τ2, time 
constant for the second component; MRT, mean response time describing the overall kinetics 
response; T63, time to reach 63% of the overall response determined independent of modeling 
procedures; Δ1PO2mv/τ1, parameter describing the relative rate of PO2mv fall.  *p<0.05 versus 
control. 
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Figure 4.1. Effects SMTC and L-NAME on the hypotensive response to ACh 
 
Effects of SMTC (0.56 mg/kg) and L-NAME (10 mg/kg) on the time to 50% recovery of the 
hypotensive response to ACh injections.  *p<0.05 versus control and SMTC. 
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Figure 4.2. Effects of SMTC infusion on PO2mv 
 
Average PO2mv during infusion for control and SMTC (0.56 mg/kg) conditions.  *p<0.05 versus 
control for end-infusion PO2mv.  Time “0” depicts initiation of saline (control) or SMTC 
infusion. 6 second averages are shown. 
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Figure 4.3. Effects of nNOS inhibition on contracting muscle PO2mv 
 
Average absolute (top panel) and normalized (bottom panel) PO2mv profiles during contractions 
for control and SMTC (0.56 mg/kg) conditions.  The inset shows the average model fits for 
control (solid line) and SMTC (dashed line) conditions.  Time “0” depicts onset of contractions. 
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Figure 4.4. Effects of nNOS inhibition on spinotrapezius muscle blood flow and VC 
 
Effects of SMTC (0.56 mg/kg) on spinotrapezius muscle blood flow (top panel) and vascular 
conductance (VC, bottom panel) at rest and during contractions.  *p<0.05 versus control. 
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Figure 4.5. Effects of nNOS inhibition on spinotrapezius muscle 2OV
  
 
Effects of SMTC (0.56 mg/kg) on spinotrapezius muscle O2 consumption ( )2OV

 at rest and 
during contractions.  *p<0.05 versus control. 
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Figure 4.6. Effects of nNOS inhibition on spinotrapezius muscle force production 
 
Effects of SMTC (0.56 mg/kg) on spinotrapezius muscle force production.  The force-time 
integral was increased significantly (p<0.05) after SMTC versus control. 
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Chapter 5 - Neuronal nitric oxide synthase inhibition and regional 
sympathetic nerve discharge: implications for peripheral vascular 
control 
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 Summary 
Neuronal nitric oxide (NO) synthase (nNOS) inhibition with systemically-administered 
S-methyl-L-thiocitrulline (SMTC) elevates mean arterial pressure (MAP) and reduces rat 
hindlimb skeletal muscle and renal blood flow.  We tested the hypothesis that those SMTC-
induced cardiovascular effects resulted, in part, from increased sympathetic nerve discharge 
(SND).  MAP, HR, and lumbar and renal SND (direct nerve recordings) were measured in 9 
baroreceptor (sino-aortic)-denervated rats for 20 minutes each following both saline and SMTC 
(0.56 mg/kg i.v.).  SMTC increased MAP (peak Δ MAP: 50±8 mmHg, p<0.01) compared to 
saline.  Lumbar and renal SND were not different between saline and SMTC conditions at any 
time (p>0.05).  The Δ SND between saline and SMTC conditions for the lumbar and renal nerves 
were not different from zero (peak Δ SND, lumbar: 2.0±6.8%; renal: 9.7±9.0%, p>0.05 versus 
zero for both).  These data support that SMTC-induced reductions in skeletal muscle and renal 
blood flow reported previously reflect peripheral nNOS-derived NO vascular control as opposed 
to increased sympathetic vasoconstriction. 
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 Introduction 
Nitric oxide (NO) is an important biological signaling molecule that exerts profound 
cardiovascular influences.  In healthy subjects NO is produced from two distinct constitutively 
expressed NO synthase (NOS) isoforms: endothelial NOS (eNOS) and neuronal NOS (nNOS).  
Since the identification of endothelial-derived relaxing factor as NO (14), NO-mediated 
peripheral vascular modulation is often attributed to eNOS (6, 19).  However, studies utilizing 
mice lacking nNOS (7, 22, 23) and acute pharmacological selective nNOS inhibition (13, 15) 
have unveiled novel cardiovascular roles specifically for nNOS-derived NO.  For example, 
nNOS-derived NO regulates mean arterial blood pressure (MAP; 12, 16, 25) via central 
modulation of sympathetic outflow (1) and basal (5, 20) and contracting skeletal muscle (4, 22) 
vascular control. 
Although a variety of nNOS inhibitors are available (15), S-methyl-L-thiocitrulline 
(SMTC) is a particularly potent and selective nNOS inhibitor in vitro and in vivo (8, 16, 25).  
nNOS inhibition via systemically-administered SMTC in rats evokes global hemodynamic 
effects including elevations in MAP and reductions in heart rate (HR; 4, 5, 25) consequent, at 
least in part, to peripheral vasoconstriction as evidenced by reductions in hindlimb skeletal 
muscle and renal blood flow and vascular conductance (VC; 3, 5, 12, 25).  It is unknown, 
however, whether the SMTC-induced hindlimb skeletal muscle and renal vasoconstriction are 
mediated via alterations in regional sympathetic outflow and increases in lumbar and renal 
sympathetic nerve discharge (SND), respectively, or, alternatively, reflect peripheral nNOS-
derived NO modulation of vascular tone.  Moreover, SMTC-induced MAP elevations and 
concurrent reductions in HR (4, 5, 25) suggest that the baroreflex may mask full expression of 
the nNOS-derived NO arterial blood pressure and vascular control signals.  These are crucial 
issues to address in order to enhance our understanding of the specific contribution of nNOS-
derived NO to cardiovascular control and peripheral vascular regulation.  
The purpose of the present investigation was to examine whether selective nNOS 
inhibition with systemic SMTC administration impacts regional SND.  We tested the specific 
hypothesis that systemically-administered SMTC in baroreceptor-denervated rats would elevate 
MAP consequent, at least in part, to increased lumbar and renal SND. 
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 Methods 
Animal care and experimental approval 
Nine young adult (4-5 months old, 412±23 g) male Sprague-Dawley rats (Charles River 
Laboratories, Wilmington, MA, USA) were utilized in the present investigation.  Rats were 
housed 2 per cage in accredited facilities on a 12:12 hour light/dark cycle with standard rat chow 
and water provided ad libitum.  All experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Kansas State University and conducted according to 
National Institute of Health guidelines.  
 
Surgical preparation 
 Anesthesia was induced by isoflurane (3–5%) and maintained during surgical procedures 
using isoflurane (1.25–1.75%), α-chloralose (80 mg/kg i.p.), and urethane (800 mg/kg i.p.). 
Catheters (PE-50) were placed in the femoral vein and femoral artery.  Maintenance doses of α-
chloralose (35–45 mg/kg/hr) were administered intravenously, whereas maintenance doses of 
urethane (200 mg/kg every 4 h) were administered intraperitoneally.  The trachea was cannulated 
and rats were artificially ventilated.  Femoral arterial pressure was monitored using a pressure 
transducer connected to a blood pressure analyzer. HR was derived from the pulsatile arterial 
pressure output of the blood pressure analyzer. Core temperature was measured with a rectal 
thermistor probe and maintained at ~37–38°C during surgical interventions by a temperature-
controlled table. Adequacy of anesthesia was indicated by an inability of mechanical stimulation 
of the hindlimb or tail to increase SND or MAP. 
To eliminate baroreceptor-mediated afferent feedback that can alter central SND 
responses, experiments were conducted in baroreceptor (sino-aortic)-denervated (SAD) rats.  
Bilateral denervation of the aortic arch was completed by cutting the superior laryngeal nerve 
near its junction with the vagus nerve and removal of the superior cervical ganglion. Bilateral 
carotid sinus denervation was completed by removal of the adventitia from the area of the carotid 
sinus bifurcation. SADs were completed 3–4 hours before initiation of experimental protocols. 
The coherence function relating arterial pressure to SND was used to demonstrate the efficacy of 
the denervation procedure (11). Coherence analysis provides a measure of the strength of linear 
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correlation of two signals as a function of frequency. The lack of coherence between arterial 
pressure and SND at the frequency of the HR demonstrated a complete SAD (11). 
 The left renal nerve was isolated retroperitoneally whereas the left lumbar nerve was 
isolated from a midline approach.  Nerve-electrode preparations were covered with silicone gel 
to prevent exposure to room air.  SND was measured and recorded biphasically with a platinum 
bipolar electrode after capacity-coupled preamplification (bandpass 30-3,000 Hz) from the 
central end of cut or distally crushed lumbar or renal nerves.  Filtered neurograms were routed to 
an oscilloscope and a nerve traffic analyzer, where sympathetic nerve potentials were full-wave 
rectified and integrated (10-ms time constant).  Total power in lumbar and renal SND was 
quantified as microvolts × seconds (μV·s) and SND recordings were corrected for background 
noise after administration of the ganglionic blocker chlorisondamine (5 mg/kg iv).  Technical 
complications precluded renal SND recordings in 2 rats (final sample size for lumbar SND: n=9, 
renal SND: n=7).  A priori power analysis based on previously published data reporting the 
effects of  non-selective NOS inhibition on lumbar and renal SND (10) indicated that a sample 
size of 6 was required for a statistical power >0.8. 
 
Experimental protocol 
 Anesthetized rats were allowed to stabilize for 60 minutes before initiation of the 
experimental protocol.  Following stabilization, MAP, HR, and lumbar and renal SND were 
measured and recorded for an ~10-15 minute period where baseline values were determined from 
the average of the final ~60 seconds (baseline values are represented as time “zero” in Figures 
5.2 and 5.3).  Rats were then administered, in random order, SMTC (0.56 mg/kg dissolved in 0.5 
ml heparanized saline; Sigma-Aldrich, St. Louis, MO, USA) or saline (0.5 ml) into the femoral 
vein catheter and MAP, HR and lumbar and renal SND were measured and recorded 
continuously for 20 minutes following each infusion.  Following the initial infusion and 20 
minute measurement period baseline values were determined as described above following a 
second ~5 minute stabilization period.  SMTC is a highly selective inhibitor of nNOS versus 
eNOS both in vitro and in vivo (8, 16, 25) and this SMTC dose has been utilized recently in our 
laboratory to assess nNOS-mediated cardiovascular and skeletal muscle function in healthy (4, 
5), heart failure (3), and senescent (9) rats (see Experimental considerations for further details 
regarding efficacy and selectivity of nNOS inhibition with SMTC).  In one rat, a short bout of 
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combined hypoxia and hypercapnia (i.e., shutting off the mechanical ventilator for ~20 seconds) 
was implemented as a positive control following saline and SMTC in which it was confirmed 
that a physiological increase in SND could be detected following completion of the experimental 
protocol (Figure 6.1 inset).  There were no qualitative or quantitative differences in MAP, HR, or 
lumbar and renal SND depending on the order of experimental conditions.  For each rat the 
entire experiment (including surgery, stabilization, and experimental protocol) lasted ~6-8 hours.  
Following the experimental protocol rats were euthanized by an overdose of methohexital 
sodium (150 mg/kg i.v.). 
 
Statistical analysis 
Data are expressed as mean±SEM.  MAP, HR, and lumbar and renal SND were 
compared between saline and SMTC conditions via paired Student’s t-test (uncorrected for 
multiple comparisons).  The differences between saline and SMTC conditions (i.e., SMTC-
saline) were compared to “zero” via z-tests (2).  This multi-statistical approach was utilized in 
order to improve the ability to detect a difference between saline and SMTC conditions should 
one exist (see Experimental considerations for more details).  Significance was accepted at 
p<0.05. 
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 Results 
Effects of nNOS inhibition with SMTC on lumbar and renal SND 
 Original tracings of lumbar and renal SND recordings for the different experimental 
conditions from a representative rat are shown in Figure 5.1.  Note the similarity among baseline, 
saline, and SMTC conditions whereas subsequent combined hypoxia and hypercapnia markedly 
augmented SND (Figure 5.1 inset) which serves as a positive physiological control and 
establishes that increased SND, should it occur, can be detected.  Specifically, there were no 
differences between saline and SMTC conditions for lumbar or renal SND at any time (Figure 
5.2, top panels).  The Δ SND between saline and SMTC conditions (SMTC-saline) for the 
lumbar and renal nerve were not different from zero at any time (Figure 5.2, bottom panels). 
 
Effects of nNOS inhibition with SMTC on MAP and HR 
SMTC administration increased MAP significantly compared to saline (Figure 5.3).  
Specifically, significant MAP elevations compared to saline were evident within 1 minute 
following SMTC infusion and this significant elevation persisted for 10 minutes.  MAP was not 
different between saline and SMTC conditions at 15 and 20 minutes following infusion.  HR was 
not different between saline and SMTC conditions at any time (Figure 5.3). 
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 Discussion 
 The principal novel finding of the present investigation is that selective nNOS inhibition 
with systemic SMTC administration evoked marked increases in MAP but, contrary to our 
hypothesis, did not impact lumbar or renal SND in SAD rats.  This finding suggests an important 
role for peripheral nNOS-derived NO in the regulation of MAP and vascular control.  
Specifically, these data support that systemic SMTC-induced reductions in rat hindlimb skeletal 
muscle and renal blood flow and VC observed previously by our laboratory (3, 5) and others (12, 
25) reflected substantial peripheral nNOS-derived NO vascular control in those tissues.  The 
present investigation contributes significantly to our understanding of cardiovascular regulation 
via peripheral nNOS-derived NO and has broad implications for chronic disease conditions 
associated with altered nNOS localization and/or function (24). 
 
Effects of SMTC on MAP 
 Systemic SMTC administration in SAD rats induced increases in MAP (↑~41%) which 
were markedly greater than reported previously in conscious and anesthetized baroreceptor-intact 
rats from our laboratory (↑~10-12%; 4, 5) and others (12, 25).  The significant reductions in HR 
in those previous reports (4, 5, 12, 25) and the greater MAP increases in SAD rats herein reveal 
that peripheral nNOS-derived NO pressure regulation is partially masked following systemic 
SMTC administration in baroreceptor-intact rats.  In addition, the lack of any increase in lumbar 
and renal SND identifies that SMTC-induced peripherally-mediated vasoconstriction underlies a 
substantial portion of the MAP increase. 
 The rapid (i.e., within 1 minute) SMTC-induced MAP elevations reported herein peaked 
after 2 minutes and then returned to values not different from saline within 15 minutes.  This is 
consistent with transient SMTC-induced MAP elevations reported previously (12, 25).  
Importantly, in recent investigations from our laboratory MAP, HR, and skeletal muscle and 
kidney blood flow were measured ~4-5 minutes following SMTC administration (3, 4, 5, 9).  
Thus, the present data support that those measurements occurred when the cardiovascular effects 
of SMTC were peaking. 
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Effects of systemic SMTC on lumbar and renal SND 
 Systemic SMTC administration in SAD rats did not alter lumbar or renal SND compared 
to saline.  This suggests that systemically-administered SMTC-induced reductions in hindlimb 
skeletal muscle (↓~33%; 5) and renal (↓~37-40%; 3, 5) blood flow and VC reflect important 
peripheral nNOS-derived NO vascular control.  Furthermore, given the use of rats with intact-
baroreceptors in those previous investigations, the reductions in blood flow and VC were, if 
anything, an underestimation of the peripheral nNOS-derived NO vascular control signal.   
 The present data should not be interpreted to reflect the lack of a role for nNOS-derived 
NO in the regulation of sympathetic outflow.  It has been demonstrated clearly that direct 
intracerebroventricular SMTC administration elevates MAP and enhances renal SND (21) which 
is consistent with an overall sympathoinhibitory role of central nNOS-derived NO (1, 18).  The 
present protocol cannot specifically delineate central versus peripheral effects of SMTC on 
MAP.  However, in conjunction with previous reports (5, 25), the lack of any differences 
between lumbar and renal SND in the present investigation support that peripheral nNOS 
derived-NO constitutes an important controller of hindlimb skeletal muscle and renal vascular 
tone at rest and, therefore, serves as a critical modulator of basal blood pressure.  Interestingly, 
the obligatory peripheral nNOS-derived NO vascular signal is lost in the active hindlimb skeletal 
muscle vasculature during low-speed treadmill running (5) where eNOS-derived NO presumably 
becomes the predominant NO signal in response to endothelial shear stress.  In contrast, 
obligatory peripheral nNOS-derived NO vascular control is preserved in the renal vasculature 
during treadmill running (5) and in the anesthetized rat spinotrapezius muscle during electrically-
induced contractions (4). 
 
Experimental considerations 
 A crucial consideration of the current experimental approach is the efficacy of achieving 
nNOS inhibition without impacting eNOS-mediated function.  Several key lines of evidence 
support this was achieved in the present investigation.  First, SMTC is a potent nNOS inhibitor 
which possesses a 17-fold selectivity for nNOS over eNOS in rat tissue in vivo (8) and induced 
significant increases in MAP herein.  Second, 0.56 mg/kg of SMTC (the identical dose utilized 
herein) does not attenuate the hypotensive response to rapid acetylcholine (ACh) infusion 
whereas it is blunted (smaller Δ MAP and faster recovery time) following non-selective NOS 
107 
 
inhibition with L-NAME (3, 4, 5, 9).  This is a crucial observation given that vasodilation in 
response to ACh is due, in large part, to eNOS-derived NO.  Had the SMTC dose in those reports 
been so high that eNOS was inhibited it would have manifested as an attenuated hypotensive 
response similar to that seen following L-NAME.  These important points suggest that 
efficacious nNOS inhibition occurred in the absence of any effects on eNOS-mediated function.  
 The less conservative statistical approach using t-tests uncorrected for multiple 
comparisons and z-tests increased our ability to detect a difference between saline and SMTC 
conditions should one have existed.  However, by these analyses there was no effect of SMTC on 
SND.  Applying the more conservative analyses via t-tests with Bonferroni correction and 
ANOVAs did not change this conclusion.  Post hoc analyses revealed that 477 rats would be 
needed to detect statistically-significant SMTC-induced increases in both lumbar and renal SND.  
Even if this number of experiments were to be performed, the extremely small differences in 
SND would not be expected to contribute physiologically to the marked SMTC-induced 
reductions in hindlimb skeletal muscle (↓~33%; 5) or renal (↓~37-40%; 3, 5) blood flow and VC 
reported previously. 
 
Perspectives and conclusions 
Selective nNOS inhibition with systemically-administered SMTC markedly elevated 
MAP without altering lumbar or renal SND.  Previous investigations have demonstrated that 
SMTC-induced MAP elevations occur simultaneous with reductions in rat hindlimb skeletal 
muscle and renal blood flow and VC (3, 5, 25).  Therefore, the present data reveal that those 
MAP elevations and peripheral vasoconstriction were likely not secondary to enhanced lumbar 
and renal SND but, rather, that they reflect important peripheral nNOS-derived NO vascular 
control. This contributes significantly to our current understanding of nNOS-derived NO 
cardiovascular modulation and challenges the conventional notion that eNOS-derived NO 
constitutes the principal basal NO cardiovascular control signal.  This concept/regulation has 
important implications for chronic disease conditions associated with altered nNOS 
localization/function and/or impaired vascular control (24). 
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Figure 5.1. Original tracings of lumbar and renal SND from a representative rat 
 
 
 
Original tracings of lumbar and renal sympathetic nerve discharge (SND) recordings for the 
baseline periods, saline and SMTC (0.56 mg/kg) conditions, as well as following ganglionic 
blockade via chlorisondamine from a representative rat.  The inset shows an original lumbar 
nerve recording in which combined hypoxia and hypercapnia were implemented (following 
saline and SMTC) to provide a positive physiological control and establish that increased SND, 
should it occur, can be detected. 
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Figure 5.2. Effects of saline and SMTC infusions on lumbar and renal SND 
 
 
Effects of saline and SMTC (0.56 mg/kg) infusions on lumbar (n=9) and renal (n=7) SND.  
There were no differences between saline and SMTC at any time.  Time “zero” represents pre-
saline or SMTC infusion baseline values.  Bottom panels depict the differences between saline 
and SMTC conditions (Δ SND, SMTC-saline).  There were no differences from zero at any time.  
Data are expressed as mean±SEM. 
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Figure 5.3. Effects of saline and SMTC infusions on MAP and HR 
 
 
Effects of saline and SMTC (0.56 mg/kg) infusions on MAP and HR (n=9).  Time “zero” 
represents pre-saline or SMTC infusion baseline values.  Data are expressed as mean±SEM.  
*p<0.05 versus saline. 
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Chapter 6 - Conclusions 
In conclusion, utilization of  the selective nNOS inhibitor SMTC in established models of 
exercise performance has provided compelling evidence in healthy subjects that:  1) nNOS-
derived NO plays an important role in modulating basal blood pressure and resting skeletal 
muscle perfusion, 2) nNOS-derived NO is an integral controller of skeletal muscle hyperemia 
during whole-body locomotor exercise with requisite exercise-intensity and muscle fiber-type 
dependency such that there were no effects of nNOS inhibition during low-speed running 
whereas during high-speed running nNOS inhibition reduced blood flow primarily within 
glycolytic fast-twitch muscle, 3) within skeletal muscle and associated vascular beds nNOS-
derived NO evokes vasomotor (promotes contracting muscle hyperemia), metabolic (increases 
resting and contracting steady-state 2OV
 ), and contractile (depresses overall force output and 
muscle work) effects and, therefore, impacts skeletal muscle PO2mv, and 4) that systemically-
administered SMTC does not impact renal or lumbar SND therefore indicating that the vascular 
control effects of SMTC represent the actions of peripherally-located nNOS (Figure 6.1).  The 
present data collectively supplant the conventional notions that eNOS is by far the most 
important peripheral NO source within the skeletal muscle vasculature during exercise and that 
cardiovascular disease associated impairments in vascular control and reductions in NO 
bioavailability reflect principally, and perhaps exclusively, eNOS-mediated dysfunction.  Thus, 
the mandate has been established for future therapeutic treatments aimed at increasing NO 
bioavailability in cardiovascular disease patients to target improvements in peripheral nNOS- as 
well as eNOS-mediated function. 
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Figure 6.1. Summary of results 
 
 
 
Schematic representation of the primary findings of this dissertation.  BF, blood flow; MAP, 
mean arterial pressure; 2OV
 , oxygen consumption. 
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